SEARCH
検索詳細
藥師神 公和大学院医学研究科 医科学専攻准教授
研究活動情報
■ 受賞- 2026年05月 Springer Nature, Springer Nature Editor of Distinction Awards 2026
- 2021年06月 日本輸血・細胞治療学会, 優秀演題（ポスター）, 本邦の細胞治療(造血幹細胞採取等)に関する実態調査 (細胞治療合同委員会 造血幹細胞移植関連委員会からの報告) その1
- 2015年03月 神戸大学医学部, ベストティーチャー賞, 神戸大学医学部附属病院 医師その他の賞
- BACKGROUND: Previous reports have suggested an association between cytomegalovirus (CMV) infection and bacterial or fungal infections after allogeneic hematopoietic cell transplantation (HCT). This study aimed to examine the relationship between letermovir (LTV) prophylaxis and the incidence of bacteremia and invasive fungal infections. METHODS: Using a Japanese transplant registry database, we analyzed 19,531 patients who underwent their first allogeneic HCT from 2011 to 2022. Patients who initiated LTV prophylaxis within the first week post-transplantation were classified as the LTV group. RESULTS: A total of 4915 patients in the LTV group and 14,616 in the No LTV group were analyzed. The incidence of bacteremia by day 100 was significantly lower in the LTV group compared to the No LTV group (17.4 % vs. 21.7 %, P < 0.001). In the multivariate analysis, LTV prophylaxis (HR 0.75, 95 %CI: 0.69-0.81) was found to be significantly associated with a reduced risk of bacteremia, along with neutrophil engraftment. Age >50 years, male, non-remission status, alternative donors, higher values of the hematopoietic cell transplantation-comorbidity index, poor performance status, and grade II-IV acute graft-versus-host disease were associated with an increased risk of bacteremia. LTV was associated with a reduced risk of bacteremia both within 30 days (HR 0.74, 95 %CI: 0.68-0.81) and beyond 30 days (HR 0.76, 95 %CI: 0.66-0.89) after HCT. Conversely, it was not associated with the risk of invasive aspergillosis or candidemia. CONCLUSIONS: LTV prophylaxis significantly reduced the risk of bacteremia. However, it was not associated with the risk of invasive fungal infections.2026年01月, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 32(1) (1), 102888 - 102888, 英語, 国際誌研究論文（学術雑誌）
- Immunity acquired before hematopoietic stem cell transplantation (HSCT) may decrease or disappear following HSCT, and it is unclear whether the first vaccination after HSCT in patients with an antigen exposure history before HSCT elicits a primary or secondary immune response. The Quantification of Antigen-Specific Antibody Sequence (QASAS) method enables real-time assessment of responses to SARS-CoV-2 antigen exposure through B-cell receptor (BCR) repertoire analysis. Using this method, we evaluated the disappearance of immunological memory after HSCT. First, in individuals without hematologic disorders, primary SARS-CoV-2 antigen exposure elicited no immune response at 7 days post-exposure but demonstrated activation between 14 to 21 days. In contrast, repeated exposure elicited early responses (secondary immune responses) at 7 days post-exposure. We then enrolled HSCT patients with pre-HSCT SARS-CoV-2 antigen exposure history and collected samples before and after vaccination. Despite prior exposure history, patients receiving their first vaccination after HSCT showed no response around 7 days post-exposure but responded at 14 days. In conclusion, even with pre-HSCT antigen exposure, the first vaccination after HSCT induced a primary immune response. This demonstrates that first vaccination after HSCT should be considered to induce a primary immune response, regardless of previous infection or vaccination history.2025年12月, International journal of hematology, 122(6) (6), 877 - 884, 英語, 国内誌研究論文（学術雑誌）
- OBJECTIVE: Essential thrombocythemia (ET), a life-threatening disease, is associated with increased risks of hemorrhagic and thromboembolic complications. In particular, ET during pregnancy is rare and associated with an increased risk of obstetric complications. Drug therapies are frequently administered for managing pregnant women with ET, and plateletpheresis is considered to reduce platelet (PLT) counts rapidly. CASE REPORT: A 28-year-old pregnant woman was referred to our hospital at 37 + 0/7 gestational weeks (GWs) due to severe thrombocythemia. She underwent plateletpheresis at 37 + 4/7 GWs because thrombocythemia was exacerbated. She delivered vaginally at 38 + 0/7 GWs without hemorrhagic or thromboembolic complications. She was diagnosed with ET based on a bone marrow biopsy, and ET gradually improved with medication. Thus, she and her baby were discharged without complications. CONCLUSION: Plateletpheresis is useful for preventing hemorrhagic and thromboembolic complications at delivery in pregnant women with ET and severe thrombocythemia during the antepartum period.2025年07月, Taiwanese journal of obstetrics & gynecology, 64(4) (4), 703 - 706, 英語, 国際誌研究論文（学術雑誌）
- Elsevier BV, 2025年07月, Transplantation and Cellular Therapy, 31(7) (7), 461.e1 - 461.e12研究論文（学術雑誌）
- BACKGROUND: Childhood cancer survivors (CCS) often develop late complications after their primary disease is cured. Cardiovascular disease is one of the most frequent and serious complications that significantly affects prognosis and quality of life. Early detection and appropriate intervention are expected to improve their prognosis. However, the risk factors for late cardiotoxicity in CCS are not well defined, and biomarkers that can detect cardiac dysfunction prior to the development of heart failure have not yet been established. METHODS: Medical records of childhood hematologic cancer survivors referred to our department for transitional care between January 2016 and October 2023 were reviewed for this cross-sectional study. The relationships between the most recent cardiac function at the review and history of cancer treatment were analyzed. RESULTS: This study included 34 patients and the median elapsed time since cancer diagnosis was 16.5 years (range, 5-30 years). None of the patients had symptomatic cardiac complications. The E/e' ratio was significantly higher in survivors with a history of hematopoietic stem cell transplantation (HSCT) than in those who did not undergo HSCT (median, 8.4% vs. 6.25%, P = 0.040), while no intergroup differences were observed in ejection fraction (EF), global longitudinal strain (GLS), or the brain natriuretic protein (BNP) level. In addition, the E/e' ratio was positively correlated with years elapsed since cancer diagnosis (ρ = 0.38, P = 0.034). While there was no clear correlation between years since cancer diagnosis and the BNP level in the overall cohort, a strong correlation was found in patients with a history of HSCT (ρ = 0.73; P < 0.01). No significant differences were observed in EF, E/e' ratio, GLS, and BNP level by cumulative anthracycline dose or history of chest irradiation. CONCLUSIONS: In this study, no patient had late symptomatic cardiac complications. However, in those who had survived for a long time since their cancer diagnosis, particularly those with a history of HSCT, there were significant elevations in the E/e' ratio and the BNP level. Continuous follow-up is required to determine whether these abnormalities lead to symptomatic cardiotoxicity and whether they serve as useful markers for the early detection of cardiac complications.2025年06月, Cardio-oncology (London, England), 11(1) (1), 55 - 55, 英語, 国際誌研究論文（学術雑誌）
- The impact of center volume on outcomes in pediatric hematopoietic cell transplantation (HCT) is not well established. We retrospectively analyzed data from a nationwide registry, including 6966 pediatric patients who underwent their first allogeneic HCT at 123 centers in Japan between 2001 and 2020. Centers were categorized by transplant volume as low volume centers (C1, the smallest number of transplantation), medium-low volume centers (C2), medium-high volume centers (C3), and high volume centers (C4, the greatest number of transplantation), and outcomes were compared across these categories. The analysis revealed no statistically significant differences in HCT outcomes among center categories. The 5-year OS by center category was 66.8% (95% CI 64.4-69.0%) for C1, 66.8% (95% CI 64.5-69.0%) for C2, 67.9% (95% CI 65.6-70.2%) for C3, and 68.3% (95% CI 65.9-70.6%) for C4. These results were consistent even when analysis was restricted to malignant and nonmalignant diseases. Our findings suggest that, unlike in adult HCT, outcomes for pediatric HCT are not significantly affected by center volume. These results indicate the consistent quality of care across centers, supporting the accessibility of HCT at various institutions for pediatric patients.2025年06月, Bone marrow transplantation, 60(6) (6), 851 - 856, 英語, 国際誌研究論文（学術雑誌）
- We report a rare case of pseudohypercalcemia associated with multiple myeloma in a 77-year-old woman. Despite elevated albumin-corrected calcium levels (12.6 mg/dL), ionized calcium levels remained normal (1.25 mmol/L). Differential diagnoses excluded common causes of hypercalcemia, and the findings suggested calcium binding to negatively charged immunoglobulins and confirmed pseudohypercalcemia due to IgG-type myeloma. Treatment with isatuximab plus dexamethasone normalized albumin-corrected calcium levels as IgG levels decreased. This report highlights the importance of recognizing pseudohypercalcemia to prevent misdiagnosis of true hypercalcemia due to myeloma. Measuring ionized calcium levels is crucial for accurate diagnosis when hypercalcemia is suspected without corresponding clinical symptoms.2025年05月, The Kobe journal of medical sciences, 71(2) (2), E46-E49, 英語, 国内誌研究論文（学術雑誌）
- ABSTRACT Although second allogeneic hematopoietic cell transplantation HCT (HCT2) is a potentially curative treatment for patients relapsing after their first HCT (HCT1), it is associated with higher non‐relapse mortality (NRM) compared with HCT1. Furthermore, while reduced‐intensity conditioning (RIC) in HCT2 might decrease NRM, there is no consensus on which patients may benefit from RIC. We retrospectively analyzed 2478 patients who underwent HCT2 for relapse of hematologic malignancies after HCT1. In a multivariate analysis, older recipient age, short duration between HCT1 and HCT2, RIC in HCT1, HCT‐CI ≥ 2, and ECOG PS ≥ 2 were associated with an increased risk of NRM. RIC in HCT2 was associated with better NRM compared to myeloablative conditioning (MAC) (hazard ratio [HR] 0.83, 95% confidence interval [CI]: 0.72–0.97; p = 0.018), but was not significantly associated with overall survival (OS) (HR 0.91, 95% CI: 0.82–1.01; p = 0.075). We observed a significant interaction for NRM between extensive cGVHD in HCT1 and the conditioning intensity of HCT2 (interaction p < 0.001), meaning that the benefit of RIC in HCT2 was seen in patients with extensive cGVHD in HCT1, but not in those without cGVHD. RIC in HCT2 was also associated with superior OS in patients with extensive cGVHD in HCT1 (HR 0.68, 95% CI: 0.49–0.93; p = 0.02), with significant interaction between the conditioning intensity and the prior history of extensive cGVHD (interaction p = 0.01). This study suggests that RIC in HCT2 reduces NRM for HCT2 and improves OS, especially in patients with a history of extensive cGVHD.Wiley, 2025年05月, American Journal of Hematology, 100(7) (7), 1185 - 1195[査読有り]研究論文（学術雑誌）
- Wiley, 2025年05月, International Journal of Laboratory Hematology, 47(5) (5), 791 - 793研究論文（学術雑誌）
- ABSTRACT Sinusoidal obstruction syndrome/veno‐occlusive disease (SOS/VOD) is a lethal complication of allogeneic hematopoietic stem cell transplantation (allo‐HSCT). According to the 2016 European Society for Blood and Marrow Transplantation criteria, SOS/VOD is classified into classical SOS/VOD and late‐onset SOS/VOD, but their similarities and differences remain unclear. Here we retrospectively investigated the incidence, risk factors, and impact on transplant outcomes of classical and late‐onset SOS/VOD in 16 518 allo‐HSCT recipients using the Japanese nationwide registry data. The cumulative incidences of classical and late‐onset SOS/VOD were 2.5% and 2.2%, with a median onset of 13 and 42 days after transplantation, respectively. Both patients with classical (hazard ratio [HR], 3.45; 95% CI, 3.07–3.87) and late‐onset (HR, 3.98; 95% CI, 3.51–4.51) SOS/VOD had a significantly worse overall survival compared with those without. The risk factors for classical and late‐onset SOS/VOD are different. Hepatic comorbidities, high‐risk diseases, use of melphalan (MEL), and myeloablative conditioning are associated with both types of SOS/VOD. Whereas poor performance status, a prior history of transplantation, and positive hepatitis C virus are associated with only classical SOS/VOD, allo‐HSCT from cord blood or related human leukocyte antigen‐haploidentical donors, use of total body irradiation and busulfan (BU), and tacrolimus‐based graft‐versus‐host disease prophylaxis are associated with only late‐onset SOS/VOD. In particular, the incidence of late‐onset SOS/VOD is much higher in patients receiving both BU‐ and MEL‐containing conditioning regimens. These findings suggest that different monitoring and treatment approaches are necessary for allo‐HSCT recipients at high risk for classical and late‐onset SOS/VOD.Wiley, 2025年05月, American Journal of Hematology, 100(8) (8), 1283 - 1294[査読有り]研究論文（学術雑誌）
- Although the hematopoietic cell transplantation (HCT)-comorbidity index (HCT-CI) score is associated with an increased risk of mortality after allogeneic HCT, it remains unclear how pre-HCT liver dysfunction affects clinical outcomes. We retrospectively compared clinical HCT outcomes among four groups stratified according to the presence of HCT-CI liver and other organ scores, using a Japan transplant registry database between 2010 and 2020. Of the 14235 recipients, 1527 tested positive for an HCT-CI liver score including HBV or HCV hepatitis (n = 503). The 5-year overall survival (OS) was significantly lower in the HCT-CI liver(+) other(+) and HCT-CI liver(-) other(+) groups compared to the HCT-CI liver(+) other(-) and HCT-CI liver(-) other(-) groups [49.9% vs. 59% vs. 66.5% vs. 68.3%, p < 0.001]. A multivariate analysis showed that both the HCT-CI liver(+) other(+) [HR 1.62, p < 0.001] and HCT-CI liver(-) other(+) groups [HR 1.21, p < 0.001] were significantly associated with inferior OS. Similarly, both the HCT-CI liver(+) other(+) [HR 1.89, p < 0.001] and liver(-) other(+) groups [HR 1.26, p < 0.001] were significantly associated with an increased risk of NRM. On the other hand, the HCT-CI liver(+) other(-) group was not associated with either OS or NRM. Separately analyzing the subcohorts with or without HCT-CI other scores, the presence of an HCT-CI liver score alone did not affect survival, while the co-presence of pretransplant liver dysfunction seemed to synergistically increase the adverse impact on OS and NRM among recipients with other organ comorbidities. Further studies will be needed to identify optimal strategies for recipients with pretransplant liver dysfunction.2025年05月, American journal of hematology, 100(5) (5), 821 - 829, 英語, 国際誌研究論文（学術雑誌）
- Abstract A retrospective study of extranodal natural killer/T-cell lymphoma (ENKL) patients diagnosed between 2014 and 2021 in Japan was conducted. Among 351 patients with sufficient data, 116 (33%) were in the advanced stage (5 in stage III and 111 in stage IV) at diagnosis, and were further analyzed. The median age was 60 years (range: 19–90), and 68 (59%) were male. Ninety-four (85%) of stage IV patients had two or more extranodal involvements. The most common first-line regimen was SMILE (steroid, methotrexate, ifosfamide, L-asparaginase, and etoposide; 52%). The 2-year overall survival (OS) for all patients was 38.5%, which was significantly improved after 2017 (25.2% for 2014–2017 vs. 50.7% for 2018–2021; P = 0.008). Patients treated with SMILE showed better OS than those treated with DeVIC or CHOP (2y-OS: 57.1%, 35.8%, and 0%, respectively; P < 0.001). The prognosis was significantly better in patients who received hematopoietic stem cell transplantation (HSCT) than in those who did not (2-year OS: 68.3% vs. 17.6%, P < 0.001). Multivariate analysis showed SMILE and HSCT were significant factors for OS. In conclusion, the prognosis of advanced-stage ENKL has improved in recent years. The L-asparaginase-containing chemotherapy and subsequent HSCT is considered the recommended strategy.Springer Science and Business Media LLC, 2025年02月, Leukemia, 39(4) (4), 909 - 916[査読有り]研究論文（学術雑誌）
- Allogeneic hematopoietic stem cell transplantation from a female donor to a male recipient (female-to-male allo-HCT) is a well-established risk factor for chronic graft-versus-host disease (GVHD) and non-relapse mortality (NRM). The inferior outcomes of female-to-male allo-HCT are considered to be due to allo-immunity against H-Y antigens. However, the influence of minor histocompatibility antigens in haplo-identical allo-HCT remains to be elucidated. We investigated the impact of female-to-male allo-HCT according to the haplo-HCT subtype. In the post-transplant cyclophosphamide (PTCY) cohort (n = 660), a female-to-male sex-mismatch was significantly associated with a decreased risk of relapse (HR: 0.70 [95% CI: 0.49-0.99], P = 0.045), but not with overall survival (OS) or NRM (HR: OS 0.89 [95% CI: 0.68-1.16], P = 0.40; NRM 0.98 [95% CI: 0.68-1.41], P = 0.90). On the other hand, in the non-PTCY cohort (n = 219), a female-to-male sex-mismatch was associated with inferior risks of OS and NRM, but was not associated with relapse. These results suggested that the survival impact of the haplo-HCT subtype differed according to the presence of a sex-mismatch. PTCY might be feasible for overcoming the inferiority of female-to-male allo-HCT and might preserve a GVL effect against H-Y antigens.2025年02月, Cytotherapy, 27(2) (2), 213 - 221, 英語, 国際誌研究論文（学術雑誌）
- 2024年11月, Bone marrow transplantation, 59(11) (11), 1628 - 1630, 英語, 国際誌
- (一社)日本血液学会, 2024年10月, 日本血液学会学術集会, 86回, O2 - 3, 英語日常的に計算可能な臨床的指標と、類洞閉塞症候群(SOS/VOD)の病勢進行との関連
- (一社)日本血液学会, 2024年10月, 日本血液学会学術集会, 86回, O2 - 4, 英語B細胞リンパ腫に対するマクロファージ標的療法のヒト化マウスモデルを用いた前臨床評価
- The impact of letermovir (LTV)-an anti-cytomegalovirus (CMV) drug-on human herpesvirus-6 (HHV-6) encephalitis is unclear. We hypothesized that LTV prophylaxis may increase the incidence of HHV-6 encephalitis by reducing anti-CMV therapies after allogeneic hematopoietic stem cell transplantation (HSCT). To evaluate the association between HHV-6 encephalitis and antiviral prophylaxis, 7985 adult patients from a nationwide registry who underwent their first HSCT between January 2019 and December 2021 were analyzed. The incidence of HHV-6 encephalitis on day 100 after HSCT was 3.6%; 11.5% for the broad-spectrum antiviral group (foscarnet, ganciclovir, or valganciclovir); 2.8% for the LTV group, and 3.8% for the other antiviral group (p < 0.001). These differences persisted when cord blood transplantation (CBT) was analyzed separately (14.1%, 5.9%, and 7.4%, p < 0.001). In the multivariate analysis, CBT (hazard ratio [HR]: 2.90), broad-spectrum antiviral prophylaxis (HR: 1.91), and grade II-IV acute graft-versus-host disease requiring systemic corticosteroids (HR: 2.42) were independent risk factors for encephalitis (all p < 0.001). The findings of this large modern database study indicate that broad-spectrum antiviral prophylaxis, rather than LTV prophylaxis, is paradoxically associated with HHV-6 encephalitis in the LTV era. This paradoxical finding needs to be further explored in future studies.2024年09月, Bone marrow transplantation, 59(9) (9), 1224 - 1231, 英語, 国際誌研究論文（学術雑誌）
- Monovalent Omicron XBB.1.5 mRNA vaccines were newly developed and approved by the FDA in Autumn 2023 for preventing COVID-19. However, clinical efficacy for these vaccines is currently lacking. We previously established the quantification of antigen-specific antibody sequence (QASAS) method to assess the response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination at the mRNA level using B-cell receptor (BCR) repertoire assay and the coronavirus antibody database (CoV-AbDab). Here, we used this method to evaluate the immunogenicity of monovalent XBB.1.5 vaccines. We analyzed repeated blood samples of healthy volunteers before and after monovalent XBB.1.5 vaccination (BNT162b2 XBB.1.5 or mRNA-1273.815) for the BCR repertoire to assess BCR/antibody sequences that matched SARS-CoV-2-specific sequences in the database. The number of matched unique sequences and their total reads quickly increased 1 week after vaccination. Matched sequences included those bound to the Omicron strain and Omicron XBB sublineage. The antibody sequences that can bind to the Omicron strain and XBB sublineage revealed that the monovalent XBB.1.5 vaccines showed a stronger response than previous vaccines or SARS-CoV-2 infection before the emergence of XBB sublineage. The QASAS method was able to demonstrate the immunogenic effect of monovalent XBB.1.5 vaccines for the 2023-2024 COVID-19 vaccination campaign.2024年08月, EJHaem, 5(4) (4), 661 - 668, 英語, 国際誌研究論文（学術雑誌）
- Wiley, 2024年06月, International Journal of Laboratory Hematology, 46(6) (6), 988 - 990研究論文（学術雑誌）
- 2024年06月, Cytotherapy, 26(11) (11), 1353 - 1361, 英語, 国際誌研究論文（学術雑誌）
- Sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD) is a life-threatening complication of hematopoietic stem cell transplantation (HSCT). Early diagnosis of SOS/VOD is associated with improved clinical outcomes. In 2023, the refined European Society for Blood and Marrow Transplantation diagnostic and severity criteria (refined EBMT criteria 2023) have been advocated. The revision has introduced new diagnostic categories, namely; probable, clinical, and proven SOS/VOD. In addition, the Sequential Organ Failure Assessment (SOFA) score has been newly incorporated into the SOS/VOD severity grading. We performed a retrospective analysis to evaluate the utility of these criteria. We analyzed 161 cases who underwent allogeneic HSCT. We identified 53 probable, 23 clinical, and 4 proven SOS/VOD cases. Probable SOS/VOD was diagnosed a median of 5.0 days earlier (interquartile range: 2-13 days, P < 0.001) than that of clinical SOS/VOD. The development of probable SOS/VOD alone was associated with a significantly inferior survival proportion compared to non-SOS/VOD (100-day survival, 86.2% vs. 94.3%, P = 0.012). The SOFA score contributed to the prediction of prognosis. Consequently, the refined EBMT criteria 2023 demonstrated the utility of SOS/VOD diagnosis and severity grading. Further investigations and improvements in these criteria are warranted.2024年04月, Bone marrow transplantation, 59(4) (4), 518 - 525, 英語, 国際誌研究論文（学術雑誌）
- Various complications can influence hematopoietic cell transplantation (HCT) outcomes. Renal complications can occur during the early to late phases of HCT along with various factors. However, studies focusing on fatal renal complications (FRCs) are scarce. Herein, we analyzed 36,596 first allogeneic HCT recipients retrospectively. Overall, 782 patients died of FRCs at a median of 108 (range, 0-3,440) days after HCT. The cumulative incidence of FRCs was 1.7% and 2.2% at one and five years, respectively. FRCs were associated with older age, male sex, non-complete remission (non-CR), lower performance status (PS), and HCT comorbidity index (HCT-CI) associated with renal comorbidity in multivariate analysis. The risk factors within 100 days included older age, multiple myeloma, PS, and HCT-CI comorbidities (psychiatric disturbance, hepatic disease, obesity, and renal disease). Older age and male sex were risk factors between 100 days and one year. After one year, HCT-CI was associated with the presence of diabetes and prior solid tumor; total body irradiation was identified as a risk factor. Non-CR was a common risk factor in all three phases. Furthermore, acute and chronic graft-versus-host disease, reactivation of cytomegalovirus, and relapse of underlying disease also affected FRCs. Systematic follow-up may be necessary based on the patients' risk factors and post-HCT events.2024年03月, Bone marrow transplantation, 59(3) (3), 325 - 333, 英語, 国際誌研究論文（学術雑誌）
- BACKGROUND: Rituximab, an anti-CD20 monoclonal antibody, can cause infusion reactions (IRs), especially during the initial rituximab infusion therapy. Generally, patients are administered a histamine H1-receptor antagonist before the rituximab infusion, along with an antipyretic analgesic, to prevent or reduce IRs. Multiple retrospective case-control studies indicate that the second generation of histamine H1-receptor antagonists might be more effective than the first generation in suppressing IRs caused by the rituximab infusion. OBJECTIVE: This study aimed to assess the efficacy of first- and second-generation histamine H1-receptor antagonists for preventing IRs resulting from the initial infusion of rituximab in patients diagnosed with non-Hodgkin lymphoma. METHODS: This is a phase II, double-blind, active-controlled randomized trial. It will be a multicenter study conducted across 3 facilities that aims to enroll a total of 40 patients diagnosed with non-Hodgkin lymphoma who will receive their initial rituximab infusion. Participating patients will be administered hydroxyzine pamoate or bepotastine besilate, representing first- or second-generation histamine H1-receptor antagonists, respectively. This will be combined with 400-mg acetaminophen tablets taken approximately 30 minutes before the first infusion of rituximab. The primary end point of this trial is to assess severe IRs, equivalent to grade 2 or higher as defined by the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0, that occur within a 4-hour period after the initiation of rituximab infusion. The secondary end points include assessing the severity of the initial IR, the maximum severity of the IR, and the duration between rituximab infusion initiation and the onset of the first IR within a 4-hour period. Additionally, the trial will evaluate histamine H1-receptor antagonist-induced drowsiness using the visual analogue scale, with each patient providing their individual response. RESULTS: This study began with patient recruitment in April 2023, with 17 participants enrolled as of November 12, 2023. The anticipated study completion is set for February 2026. CONCLUSIONS: This study is the first randomized controlled trial comparing the effects of oral first- and second-generation histamine H1-receptor antagonists in preventing IRs induced by the initial administration of rituximab. The findings from this study hold the potential to establish the rationale for a phase III study aimed at determining the standard premedication protocol for rituximab infusion. TRIAL REGISTRATION: Japan Registry of Clinical Trials jRCTs051220169; https://jrct.niph.go.jp/latest-detail/jRCTs051220169. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/54882.2024年02月, JMIR research protocols, 13, e54882, 英語, 国際誌研究論文（学術雑誌）
- Intrathecal chemotherapy is often administered for prophylaxis and treatment of central nervous system involvement in hematological malignancies. However, it may rarely cause neurotoxicity as a side effect. We herein report a 74-year-old woman with diffuse large B-cell lymphoma including a spinal lesion. She received systemic and intrathecal chemotherapy. After five doses of intrathecal chemotherapy, she developed intrathecal chemotherapy-induced myelopathy. Intrathecal treatment was discontinued, and she was administered vitamin B12 and folic acid, along with steroid pulses. However, her symptoms did not improve. Intrathecal chemotherapy-induced myelopathy is rare, but may be irreversible; therefore, clinicians should be aware of this potential complication.2024年02月, Internal medicine (Tokyo, Japan), 63(4) (4), 547 - 551, 英語, 国内誌研究論文（学術雑誌）
- BACKGROUND: Monitoring of HBV-DNA and HBV-DNA-guided preemptive therapy using nucleos(t)ide analogues (NAs) are recommended for preventing the development of hepatitis due to HBV reactivation after allogeneic hematopoietic stem cell transplantation (allo-HSCT) in recipients with resolved HBV infection. However, little is known about the appropriate duration of NA treatment and the outcomes of NAs cessation on recurrence of HBV reactivation. OBJECTIVE: To clarify the consequences of NAs cessation in recipients with resolved HBV infection who experienced HBV reactivation following allo-HSCT. STUDY DESIGN: We retrospectively reviewed the clinical records of recipients with resolved HBV infection (HBsAg-negative, anti-HBc-positive) before allo-HSCT who had been diagnosed as having HBV reactivation (HBsAg-positive and/or HBV-DNA detectable) after allo-HSCT during the period from January 2010 to December 2020. RESULTS: A total of 72 patients from 16 institutes were registered (median age of the patients, 60 years; age range, 27-73 years; 42 males and 30 females). Initial HBV reactivation was observed on day 10 to day 3034 (median, 513 days) after allo-HSCT. Anti-HBs were lost in more than 80% of the patients at the time of HBV reactivation. All 72 patients received preemptive NAs and no fatal HBV reactivation-related hepatitis was observed. There was continuous detection of HBV-DNA without hepatitis in 5 patients during the follow-up period. Administration of NAs was discontinued in 24 (33%) of 72 patients by each physician's decision. Second HBV reactivation occurred in 11 (46%) of the 24 patients in whom administration of NAs was discontinued. Duration of NA treatment were not significantly different between patients with or without second HBV reactivation. The frequency of further HBV reactivation tended to be lower in patients with anti-HBs titer of more than 10 mIU/mL at the time of NA cessation. CONCLUSION: Multiple reactivation of HBV after NA discontinuation was common in patients with HBV reactivation who received allo-HSCT despite the long duration of NA. Careful monitoring of HBV-DNA is important even after the discontinuation of NA in the case with HBV reactivation after allo-HSCT because multiple reactivations could occur. Active immunization by HB vaccine might be effective for suppressing further HBV reactivation after cessation of NAs.2024年01月, Transplantation and cellular therapy, 英語, 国際誌研究論文（学術雑誌）
- Higher rate of non-relapse mortality (NRM) remains yet to be resolved in umbilical cord blood transplantation (UCBT). Considering that UCBT has some unique features compared with allogeneic hematopoietic cell transplantation from other graft sources, a UCBT-specific NRM risk assessment system is required. Thus, in this study, we sought to develop a UCBT-specific NRM Risk Assessment (CoBRA) score. Using a nationwide registry database, we retrospectively analyzed 4437 recipients who had received their first single-unit UCBT. Using the backward elimination method, we constructed the CoBRA score in a training cohort (n = 2687), which consisted of recipients age ≥ 55 (score 2), hematopoietic cell transplantation-specific comorbidity index (HCT-CI) ≥ 3 (score 2), male recipient, graft-versus-host disease (GVHD) prophylaxis other than tacrolimus in combination with methotrexate, performance status (PS) 2-4, HLA allele mismatch ≥ 2, refined disease risk index (DRI) high-risk, myeloablative conditioning (MAC), and CD34+ cell doses < 0.82 x 105/kg (score 1 in each). The recipients were categorized into three groups: Low (0-4 points), Intermediate (5-7 points), and High (8-11 points) groups according to the CoBRA score. In the validation cohort (n = 1750), the cumulative incidence of NRM at 2 years was 14.9%, 25.5%, and 47.1% (P < 0.001), and 2-year overall survival (OS) was 74.2%, 52.7%, and 26.3% (P < 0.001) in the Low, Intermediate, and High groups, respectively. In summary, the CoBRA score could predict the NRM risk as well as OS after UCBT. Further external validation will be needed to confirm the significance of the CoBRA score.2024年01月, Blood advances, 英語, 国際誌研究論文（学術雑誌）
- A monovalent Omicron XBB.1.5 mRNA RBD analogue vaccine, MAFB-7256a (DS-5670d), was newly developed and approved in Japan in the Spring of 2024 for the prevention of COVID-19. However, clinical efficacy data for this vaccine are currently lacking. We previously established the Quantification of Antigen-specific Antibody Sequence (QASAS) method to assess the response to SARS-CoV-2 vaccination at the mRNA level using B-cell receptor (BCR) repertoire assays and the Coronavirus Antibody Database (CoV-AbDab). Here, we used this method to evaluate the immunogenicity of MAFB-7256a. We analyzed repeated blood samples using the QASAS method from three healthy volunteers before and after MAFB-7256a vaccination. BCR response increased rapidly one week post-vaccination and then decreased, as with conventional vaccine. Notably, the matched sequences after MAFB-7256a vaccination specifically bound to the receptor-binding domain (RBD), with no sequences binding to other epitopes. These results validate that MAFB-7256a is an effective vaccine that exclusively induces antibodies specific for the RBD, demonstrating its targeted immunogenic effect.2024年, Frontiers in immunology, 15, 1468760 - 1468760, 英語, 国際誌研究論文（学術雑誌）
- Tumor-associated macrophages (TAMs) are abundant in the tumor microenvironment and are considered potential targets for cancer immunotherapy. To examine the antitumor effects of agents targeting human TAMs in vivo, we here established preclinical tumor xenograft models based on immunodeficient mice that express multiple human cytokines and have been reconstituted with a human immune system by transplantation of human CD34+ hematopoietic stem and progenitor cells (HIS-MITRG mice). HIS-MITRG mice supported the growth of both human cell line (Raji)– and patient-derived B cell lymphoma as well as the infiltration of human macrophages into their tumors. We examined the potential antitumor action of an antibody to human SIRPα (SE12C3) that inhibits the interaction of CD47 on tumor cells with SIRPα on human macrophages and thereby promotes Fcγ receptor–mediated phagocytosis of the former cells by the latter. Treatment with the combination of rituximab (antibody to human CD20) and SE12C3 inhibited Raji tumor growth in HIS-MITRG mice to a markedly greater extent than did rituximab monotherapy. This enhanced antitumor effect was dependent on human macrophages and attributable to enhanced rituximab-dependent phagocytosis of lymphoma cells by human macrophages. Treatment with rituximab and SE12C3 also induced reprogramming of human TAMs toward a proinflammatory phenotype. Furthermore, the combination treatment essentially prevented the growth of patient-derived diffuse large B cell lymphoma in HIS-MITRG mice. Our findings thus support the study of HIS-MITRG mice as a model for the preclinical evaluation in vivo of potential therapeutics, such as antibodies to human SIRPα, that target human TAMs.Frontiers Media SA, 2023年12月, Frontiers in Immunology, 14, 英語, 国際誌, 国際共著している[査読有り]研究論文（学術雑誌）
- Haploidentical haematopoietic cell transplantation (haplo-HCT) using post-transplant cyclophosphamide (PTCY) as graft-versus-host disease (GVHD) prophylaxis is the standard of care for various haematological malignancies. The original PTCY dose after haplo-HCT was 100 mg/kg, but no dose-finding studies have been performed to identify the optimal dose. We performed a retrospective analysis to compare standard-dose PTCY (100 mg/kg) with reduced-dose PTCY (80 mg/kg): 969 in the standard-dose group and 538 in the reduced-dose group. As there was a significant difference between the two groups regarding patient and transplant characteristics, we performed propensity score (PS) matching. After PS matching, 425 patients in each group were included. The probabilities of 2-year OS were 55.9% in the standard-dose group and 47.0% in the reduced-dose group (p = 0.36). The cumulative incidences of 2-year non-relapse mortality were 21.3% in the standard-dose group and 20.5% in the reduced-dose group (p = 0.55). There was no significant difference in the incidence of acute (grade II-IV 29.2% [95% CI, 24.9-33.6] vs. 25.3% [95% CI, 21.3-29.6]; grade III-IV 7.3% [95% CI, 5.1-10.0] vs. 6.6% [95% CI, 4.5-9.3]) or chronic GVHD. In conclusion, reduced- and standard-dose PTCY were comparable in terms of major clinical outcomes.2023年11月, British journal of haematology, 204(3) (3), 959 - 966, 英語, 国際誌研究論文（学術雑誌）
- No mechanistic lead is known for establishing AL amyloid deposits in organs. We here report an electron microscopic (EM) analysis in a case of intestinal AL amyloidosis before initiating treatment for amyloidosis. The dense deposits of amyloid fibrils are concentrated around the small blood vessels in the submucosal area of intestinal tissue. Surprisingly, we observed endothelial cells (ECs) of blood vessels containing plenty of endocytotic (pinocytotic) and transcytotic vesicles at the luminal side and above the basement membrane, indicating the one-way active trafficking of either the immunoglobulin (Ig) light chain or preassembled amyloid fibrils from the luminal side of ECs to the extraluminal area of ECs. Immunoelectron microscopy displayed that the immuno-gold signals were observed in the vascular cavity and the subendothelial area of amyloid deposits. However, there is no sign of an Ig light chain in pinocytotic vesicles. Therefore, the intestinal ECs may actively pump out mainly the preassembled amyloid fibrils (not light chains) from the blood stream into the subendothelial area as a physiologic function.2023年11月, Experimental hematology, 英語, 国際誌[査読有り]研究論文（学術雑誌）
- Japanese Society of Internal Medicine, 2023年10月, Internal Medicine, 62(20) (20), 2949 - 2958研究論文（学術雑誌）
- BACKGROUND: We previously demonstrated that CD34 + cell transplantation in animals healed intractable fractures via osteogenesis and vasculogenesis; we also demonstrated the safety and efficacy of this cell therapy in an earlier phase I/II clinical trial conducted on seven patients with fracture nonunion. Herein, we present the results of a phase III clinical trial conducted to confirm the results of the previous phase studies using a larger cohort of patients. METHODS: CD34 + cells were mobilized via administration of granulocyte colony-stimulating factor, harvested using leukapheresis, and isolated using magnetic cell sorting. Autologous CD34 + cells were transplanted in 15 patients with tibia nonunion and 10 patients with femur nonunion, who were followed up for 52 weeks post transplantation. The main outcome was a reduction in time to heal the tibia in nonunion patients compared with that in historical control patients. We calculated the required number of patients as 15 based on the results of the phase I/II study. An independent data monitoring committee performed the radiographic assessments. Adverse events and medical device failures were recorded. RESULTS: All fractures healed during the study period. The time to radiological fracture healing was 2.8 times shorter in patients with CD34 + cell transplantation than in the historical control group (hazard ratio: 2.81 and 95% confidence interval 1.16-6.85); moreover, no safety concerns were observed. CONCLUSIONS: Our findings strongly suggest that autologous CD34 + cell transplantation is a novel treatment option for fracture nonunion. TRIAL REGISTRATION: UMIN-CTR, UMIN000022814. Registered on 22 June 2016.2023年10月, BMC medicine, 21(1) (1), 386 - 386, 英語, 国際誌研究論文（学術雑誌）
- (一社)日本血液学会, 2023年10月, 日本血液学会学術集会, 85回, 683 - 683, 英語血小板輸血不応の項を含む新診断基準による、類洞閉塞症候群(SOS)の早期診断
- The use of anti-SARS-CoV-2 antibody products like tixagevimab/cilgavimab represents an important strategy to protect immunocompromised patients with haematological malignancies from COVID-19. Although patients who receive these agents should still be vaccinated, the use of tixagevimab/cilgavimab can mask the production of anti-spike antibody after vaccination, making it hard to assess vaccine response. We have newly established a quantification method to assess the response to SARS-CoV-2 vaccination at the mRNA level using B-cell receptor (BCR) repertoire assay and the Coronavirus Antibody Database (CoV-AbDab). Repeated blood samples before and after vaccination were analysed for the BCR repertoire, and BCR sequences were searched in the database. We analysed the number and percentage frequency of matched sequences. We found that the number of matched sequences increased 2 weeks after the first vaccination and quickly decreased. Meanwhile, the number of matched sequences more rapidly increased after the second vaccination. These results show that the postvaccine immune response can be assessed at the mRNA level by analysing the fluctuation in matching sequences. Finally, BCR repertoire analysis with CoV-AbDab clearly demonstrated the response to mRNA SARS-CoV-2 vaccination even after tixagevimab/cilgavimab administration in haematological malignancy patients who underwent allogeneic haematopoietic stem cell transplantation.2023年06月, British journal of haematology, 英語, 国際誌研究論文（学術雑誌）
- BACKGROUND AIMS: Allogeneic hematopoietic stem cell transplantation from female donors to male recipients (female-to-male allo-HCT) is a well-established risk factor for a greater incidence of non-relapse mortality (NRM) and chronic graft-versus-host disease (GVHD). In contrast, unrelated cord blood transplantation (UCBT) is associated with a lower incidence of chronic GVHD. In this study, survival outcomes were compared between the UCBT and unrelated female-to-male bone marrow transplantation (UFMBMT) groups. METHODS: We evaluated male allo-HCT recipients who underwent UCBT or UFMBMT between 2012 and 2020 in Japan. There were 2517 cases in the UCBT group, 456 cases in the HLA-matched UFMBMT group and 457 cases in the HLA-mismatched UFMBMT group. RESULTS: HLA-mismatched UFMBMT was significantly associated with a decreased risk of relapse (hazard ratio [HR] 0.74; 95% confidence interval [CI] 0.57-0.98], P = 0.033) and HLA-matched UFMBMT had the tendency of a decreased risk of relapse (HR 0.78; 95% CI 0.61-1.01, P = 0.059). HLA-matched UFMBMT was also associated with favorable OS (HR 0.82; 95% CI 0.69-0.97, P = 0.021). The relationship between the donor sources and relapse was similarly observed in the lymphoid malignancy cohort. CONCLUSIONS: The difference of graft-versus leukemia effect by H-Y immunity according to donor sources might contribute to the difference in clinical impact. It might be desirable for patients who could sufficiently wait for donor coordination to select BMT rather than UCBT, even if only unrelated female donors are available for male recipients.2023年06月, Cytotherapy, 英語, 国際誌研究論文（学術雑誌）
- Abstract Sinusoidal obstruction syndrome (SOS) is a fatal complication of hematopoietic stem cell transplantation (HSCT). Early diagnosis for SOS can improve clinical outcomes significantly. Here, we performed a retrospective study to investigate the Cairo diagnostic criteria, in which SOS was defined as the development of two or more in seven events, including transfusion‐refractory thrombocytopenia. Among 154 cases of allogeneic HSCT, 10 cases of SOS using the European Society for Blood and Marrow Transplantation criteria (EBMT16) as the reference standard were identified. The original Cairo criteria could diagnose SOS 5 days earlier than any other established criteria, with some false‐positive results (sensitivity = 100.0%; specificity = 72.2%). When the cutoff was set to three events for the Cairo criteria, the diagnosis of SOS could be made 3 days earlier than that using the EBMT16 criteria, with comparable precision (specificity = 86.1%). The accuracy of the Cairo criteria improved further when the cutoff point was set to four (specificity = 93.8%). The fulfillment of the Cairo criteria was associated with high mortality. Based on our results, the Cairo criteria were also considered clinically useful, especially at three or four cutoff points. Further studies are required to validate and refine the criteria.Wiley, 2023年06月, eJHaem研究論文（学術雑誌）
- Hyperglycemia in the early days following allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a well-known risk factor for acute graft-versus-host disease (GVHD) and non-relapse mortality. The FreeStyle Libre Pro, a factory calibrated continuous glucose monitoring (CGM) device, has been used for the retrospective analysis of glucose testing in patients with diabetes. We assessed the safety and accuracy of the device in patients undergoing allo-HSCT. We recruited eight patients who underwent allo-HSCT between August 2017 and March 2020. They wore the FreeStyle Libre Pro on the day before or on the day of transplantation until 28 days after transplantation. Adverse events, especially bleeding and infection, were monitored to assess safety, and blood glucose levels were measured and compared with the device values. None of the eight participants experienced bleeding that was difficult to stop from the sensor site or local infection that required antimicrobial administration. The device value was well correlated with blood glucose (correlation coefficient r=0.795, P<0.01); however, the overall mean absolute relative difference was 32.1%±16.0%. Our study demonstrated the safety of FreeStyle Libre Pro in allo-HSCT patients. However, the sensor results tended to be lower than the blood glucose levels.2023年05月, Blood cell therapy, 6(2) (2), 54 - 60, 英語, 国内誌研究論文（学術雑誌）
- Allogeneic hematopoietic cell transplantation between female donors and male recipients (female-to-male allo-HCT) is a well-established risk factor for inferior survival outcomes due to a higher incidence of graft-versus-host disease (GVHD). However, a clinical significance of anti-thymocyte globulin (ATG) in the female-to-male allo-HCT has not been elucidated. In this study, we retrospectively evaluated male patients who underwent allo-HCT between 2012 and 2019 in Japan. In the female-to-male allo-HCT cohort (n = 828), the use of ATG was not associated with a decreased risk of GVHD (HR of acute GVHD 0.691 [95% CI: 0.461-1.04], P = 0.074; HR of chronic GVHD 1.06 [95% CI: 0.738-1.52], P = 0.76), but was associated with favorable overall survival (OS) and a decreased risk of non-relapse mortality (NRM) (HR of OS 0.603 [95% CI: 0.400-0.909], P = 0.016; HR of NRM 0.506 [95% CI: 0.300-0.856], P = 0.011). The use of ATG in female-to-male allo-HCT resulted in survival outcomes that were almost equivalent to those in the male-to-male allo-HCT group. Therefore, GVHD prophylaxis with ATG might overcome the inferiority of survival outcomes in female-to-male allo-HCT.2023年05月, Scientific reports, 13(1) (1), 7166 - 7166, 英語, 国際誌研究論文（学術雑誌）
- PURPOSE: Many effective vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been developed, but a weaker response in individuals undergoing anticancer treatment has been reported. This study evaluates the immunogenic status and safety of SARS-CoV-2 vaccines for patients with non-small-cell lung cancer (NSCLC), receiving tegafur-uracil (UFT) as postoperative adjuvant chemotherapy. METHODS: The subjects of this prospective study were 40 patients who underwent surgery for NSCLC and received SARS-CoV-2 vaccines postoperatively. We compared the antibody titers of SARS-CoV-2 vaccines and the adverse events between patients who received adjuvant UFT and patients who did not. RESULTS: The mean anti-S1 IgG titers were not significantly different between the UFT and without-UFT groups (mean optimal density, 0.194 vs. 0.205; P = 0.76). Multivariate analysis identified the period after the second vaccination as an independent predictor of anti-S1 IgG titer (P = 0.049), but not the UFT status (with or without-UFT treatment; P = 0.47). The prevalence of adverse events did not differ significantly between the groups, and no severe adverse events occurred. CONCLUSIONS: The efficacy and safety of the SARS-CoV-2 vaccines for NSCLC patients who received postoperative adjuvant UFT chemotherapy were comparable to those for NSCLC patients who did not receive postoperative adjuvant UFT chemotherapy. CLINICAL TRIAL REGISTRATION: This study was registered with the University Hospital Medical Information Network (UMIN) in Japan (UMIN000047380).2023年02月, Surgery today, 1 - 7, 英語, 国内誌研究論文（学術雑誌）
- In acute myeloid leukemia (AML), the heterogeneity of genetic and epigenetic characteristics makes treatment difficult. The prognosis for AML is therefore poor, and there is an urgent need for new treatments for this condition. Gemtuzumab ozogamicin (GO), the first antibody-drug conjugate (ADC), targets the CD33 antigen expressed in over 90% of AML cases. GO therefore has the potential to counter the heterogeneity of AML patients. However, a major clinical problem is that drug resistance to GO diminishes its effect over time. Here, we report that the inhibition of glycogen synthase kinase 3 (GSK3) alone overcomes several forms of GO resistance at concentrations without antileukemic effects. The GSK3 inhibitors tested significantly enhanced the cytotoxic effect of GO in AML cell lines. We elucidated four mechanisms of enhancement: (1) increased expression of CD33, the target antigen of GO; (2) activation of a lysosomal function essential for hydrolysis of the GO linker; (3) reduced expression of MDR1 that eliminates calicheamicin, the payload of GO; and (4) reduced expression of the anti-apoptotic factor Bcl-2. A similar combination effect was observed against patient-derived primary AML cells. Combining GO with GSK3 inhibitors may be efficacious in treating heterogeneous AML.2023年02月, EJHaem, 4(1) (1), 153 - 164, 英語, 国際誌研究論文（学術雑誌）
- Japanese Society of Internal Medicine, 2023年01月, Internal Medicine, 62(2) (2), 285 - 292研究論文（学術雑誌）
- Japanese Society for Lymphoreticular Tissue Research, 2023年, Journal of Clinical and Experimental Hematopathology, 63(4) (4), 240 - 245研究論文（学術雑誌）
- INTRODUCTION: Adoptive cell transfer of genetically engineered T cells is a promising treatment for malignancies; however, there are few ideal cancer antigens expressed on the cell surface, and the development of chimeric antigen receptor T cells (CAR-T cells) for solid tumour treatment has been slow. CAR-T cells, which recognise major histocompatibility complex and peptide complexes presented on the cell surface, can be used to target not only cell surface antigens but also intracellular antigens. We have developed a CAR-T-cell product that recognises the complex of HLA-A*02:01 and an epitope of the MAGE-A4 antigen equipped with a novel signalling domain of human GITR (investigational product code: MU-MA402C) based on preclinical studies. METHODS AND ANALYSIS: This is a dose-escalation, multi-institutional, phase 1 study to evaluate the tolerability and safety of MU-MA402C for patients with MAGE A4-positive and HLA-A*02:01-positive unresectable advanced or recurrent solid cancer. Two dose cohorts are planned: cohort 1, MU-MA402C 2×108/person; cohort 2, MU-MA402C 2×109/person. Prior to CAR-T-cell infusion, cyclophosphamide (CPA) and fludarabine (FLU) will be administered as preconditioning chemotherapy. Three evaluable subjects per cohort, for a total of 6 subjects (maximum of 12 subjects), will be recruited for this clinical trial. The primary endpoints are safety and tolerability. The severity of each adverse event will be evaluated in accordance with Common Terminology Criteria for Adverse Events V.5.0. The secondary endpoint is efficacy. Antitumour response will be evaluated according to Response Evaluation Criteria in Solid Tumours V.1.1. ETHICS AND DISSEMINATION: This clinical trial will be conducted in accordance with the current version of Good Clinical Practice. The protocol was approved by the Clinical Research Ethics Review Committee of Mie University Hospital (approval number F-2021-017). The trial results will be published in peer-reviewed journals and/or disseminated through international conferences. TRIAL REGISTRATION NUMBER: jRCT2043210077.2022年11月, BMJ open, 12(11) (11), e065109, 英語, 国際誌研究論文（学術雑誌）
- Abstract Global longitudinal strain (GLS), a new cardiac parameter measured by the speckle‐tracking method, is reportedly more sensitive than ejection fraction (EF) in detecting slight cardiac dysfunction in heart failure patients. We validated the utility of GLS in allogeneic hematopoietic stem cell transplantation (HSCT) patients during a long‐term follow‐up. Medical records of patients who underwent allogeneic HSCT between 2013 and 2020 were reviewed retrospectively. We evaluated the last echocardiography performed before transplantation and those performed annually during the 5 years after transplantation. We also investigated newly diagnosed cardiac events, which developed after HSCT. Among 85 patients, 22 used cardioprotective drugs. The median follow‐up duration in surviving patients was 54.1 months (range, 2.9–92.6 months). GLS significantly decreased year by year, and patients taking cardioprotective agents tended to have a better GLS at 5 years than at 3 years, while EF did not change. Fifteen patients developed newly diagnosed cardiac events. Multivariate analysis revealed that low GLS and high serum ferritin levels at baseline were independently associated with the development of cardiac events. Therefore, we need a continuous follow‐up of cardiac function by GLS and prescription of cardioprotective drugs might be considered for HSCT patients with low GLS. Further research is warranted.Wiley, 2022年11月, eJHaem, 4(1) (1), 192 - 198研究論文（学術雑誌）
- We previously reported that a second dose of BNT162b2 was safe and effective for allogeneic hematopoietic stem cell transplantation (HSCT) patients. Here, we investigated the safety and efficacy of a third dose of COVID-19 mRNA vaccine in allogeneic HSCT patients. Antibody titers against the S1 spike protein were measured using the QuaResearch COVID-19 Human IgM IgG ELISA kit. The previous study included 25 allogeneic HSCT patients who received two doses of BNT162b2. Following the exclusion of three patients because of the development of COVID-19 (n = 2) and loss to follow-up (n = 1), the study evaluated 22 allogeneic HSCT patients who received a third dose of COVID-19 mRNA vaccine (BNT162b2 [n = 15] and mRNA-1273 [n = 7]). Median age at the time of the first vaccination was 56 (range, 23-71) years. Five patients were receiving immunosuppressants at the third vaccination, namely calcineurin inhibitors (CI) alone (n = 1), steroids alone (n = 2), or CI combined with steroids (n = 2). Twenty-one patients (95%) seroconverted after the third dose. None of our patients had serious adverse events, new-onset graft-versus-host disease (GVHD), or GVHD exacerbation after vaccination. A third dose of the BNT162b2 and mRNA-1273 COVID-19 vaccines was safe and effective for allogeneic HSCT patients.2022年10月, Vaccines, 10(11) (11), 英語, 国際誌研究論文（学術雑誌）
- An acute promyelocytic leukemia (APL) patient not demonstrating the retinoic acid receptor α (RARA) translocation is rare. A 76-year-old man was diagnosed with myelodysplastic syndrome (MDS). After a year, abnormal promyelocytes were detected with pancytopenia and disseminated intravascular coagulopathy. Morphologically, the patient was diagnosed with APL; however, a genetic examination failed to detect RARA translocation. Thereafter, whole-genome sequencing revealed an NRAS missense mutation [c.38 G>A (p.G13D)]. This mutation was not detected in posttreatment bone marrow aspirate, despite residual MDS. Few reports are available on similar cases. Furthermore, the NRAS c.38 G>A mutation may be a novel pathogenic variant exacerbating RARA translocation-negative acute promyelocytic-like leukemia.2022年09月, Internal medicine (Tokyo, Japan), 英語, 国内誌研究論文（学術雑誌）
- OBJECTIVES: Oral corticosteroids reduce the antibody titer of the BNT162b2 mRNA vaccine against SARS-CoV-2. To date, the effect of inhaled corticosteroids on antibody titers is unknown. STUDY DESIGN: The design of this study is retrospective study. METHODS: We analyzed the relationship between the clinical features and total antibody titers against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein in 320 subjects who had never been infected with Coronavirus disease 2019 (COVID-19) and were vaccinated the second time with the BNT162b2 mRNA vaccine between October 1 to December 28, 2021. RESULTS: Of the 320 subjects, 205 were treated with inhaled corticosteroids. The median antibody titer of patients treated with inhaled corticosteroids was 572 U/mL, which was significantly higher than that of patients treated without inhaled corticosteroids (454U/mL, P = 0.00258). The median antibody titers of smokers, men, and patients aged 65 years and over, were 315.5 U/mL, 385 U/mL, and 425.5 U/mL, respectively. These results are significantly lower than those of patients who never smoked, women, and patients aged less than 64 years (582 U/mL [P < 0.0001], 682.5 U/mL [P < 0.0001], and 717 U/mL [P < 0.0001], respectively). The multivariate analysis revealed that females and age were independent antibody titer-reducing factors (P = 0.0001 and P < 0.0001, respectively). CONCLUSIONS: The use of inhaled corticosteroids did not reduce the antibody titer against SARS-CoV-2 spike protein. Clinicians should continue treatment with inhaled corticosteroids if indicated.2022年08月, Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology, 18(1) (1), 78 - 78, 英語, 国際誌研究論文（学術雑誌）
- Anti-CD20 antibodies react with CD20 expressed not only on malignant B cells, but also on normal B cells. It has been reported that patients treated with anti-CD20 antibodies had an insufficient response to two-dose mRNA SARS-CoV-2 vaccination. To investigate the efficacy of a third dose in these patients, we investigated serum IgG antibody titers for the S1 protein after a third vaccination in 22 patients treated with the anti-CD20 antibody who failed two-dose vaccination. Results showed that overall, 50% of patients seroconverted. Although no patient who received the third dose within 1 year of the last anti-CD20 antibody administration showed an increase in S1 antibody titer, 69% of patients who received the third dose more than 1 year after the last anti-CD20 antibody administration seroconverted. Our data show that a third dose of vaccination is effective in improving the seroconversion rate in patients treated with the anti-CD20 antibody who failed standard two-dose vaccination.2022年06月, Vaccines, 10(6) (6), 英語, 国際誌研究論文（学術雑誌）
- BACKGROUND: Recent pivotal phase III trials involving direct oral anticoagulant (DOAC) versus low molecular weight heparin have demonstrated the utility of DOACs in Western patients with cancer-associated venous thromboembolism (VTE). However, these trials did not include Japanese patients. This phase II trial evaluated the safety and efficacy of apixaban in Japanese patients with cancer-associated VTE (UMIN000028447). METHOD AND RESULTS: Apixaban was initiated at 10 mg twice daily for 7 days, followed by 5 mg twice daily for 23 weeks. The primary endpoint was the incidence of major or clinically relevant non-major (CRNM) bleeding events during the treatment period. The study was terminated due to safety concerns after enrolling 27 patients. Median age was 71 years; median body weight was 51.3 kg; and major primary tumor sites were the gastrointestinal tract (26%) and lung (19%). During the median follow-up period of 5.4 months, major or CRNM bleeding occurred in in 26% of patients (major, n = 5; CRNM, n = 2; 95% confidence interval, 11-46%). No recurrent VTE or VTE-related death occurred. Estimated overall survival at 6 months was 68%. CONCLUSION: This study demonstrated the excessive bleeding risk of apixaban at the standard dose in Japanese patients with cancer-associated VTE.2022年04月, International journal of hematology, 115(4) (4), 499 - 507, 英語, 国内誌研究論文（学術雑誌）
- BACKGROUND: Although COVID-19 severity in cancer patients is high, the safety and immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in patients undergoing chemotherapy for solid cancers in Japan have not been reported. METHODS: We investigated the safety and immunogenicity of BNT162b2 in 41 patients undergoing chemotherapy for solid cancers and in healthy volunteers who received 2 doses of BNT162b2. We evaluated serum IgG antibody titers for S1 protein by ELISA at pre-vaccination, prior to the second dose and 14 days after the second vaccination in 24 cancer patients undergoing cytotoxic chemotherapy (CC group), 17 cancer patients undergoing immune checkpoint inhibitor therapy (ICI group) and 12 age-matched healthy volunteers (HV group). Additionally, inflammatory cytokine levels were compared between the HV and ICI groups at pre and the next day of each vaccination. RESULTS: Anti-S1 antibody levels were significantly lower in the ICI and CC groups than in the HV group after the second dose (median optimal density: 0.241 [0.063-1.205] and 0.161 [0.07-0.857] vs 0.644 [0.259-1.498], p = 0.0024 and p < 0.0001, respectively). Adverse effect profile did not differ among the three groups, and no serious adverse event occurred. There were no differences in vaccine-induced inflammatory cytokines between the HV and ICI groups. CONCLUSION: Although there were no significant differences in adverse events in three groups, antibody titers were significantly lower in the ICI and CC groups than in the HV group. Further protection strategies should be considered in cancer patients undergoing CC or ICI.2022年04月, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 28(4) (4), 516 - 520, 英語, 国際誌研究論文（学術雑誌）
- The graft-versus-leukemia (GVL) effect is one of the curative mechanisms of allogeneic hematopoietic stem cell transplantation (allo-HCT). H-Y antigens, which are encoded by Y chromosome, are important targets of the GVL effect. Thus, deletion of the Y chromosome (del[Y]) might cause the GVL effect to deteriorate in a transplantation involving a female donor and male recipient, although the clinical significance of the del(Y) group remains to be elucidated. In this study, we evaluated adult male patients who underwent allo-HCT between 2010 and 2019 in Japan. There were 155 cases in the del(Y) group and 4149 cases without del(Y) who underwent female-to-male allo-HCT. Del(Y) was significantly associated with inferior overall survival (hazard ratio [HR], 1.24; 95% confidence interval [CI], 1.00-1.53; P = .049) and an increased risk of relapse (HR, 1.40; 95% CI, 1.08-1.80; P = .0098) in multivariate analyses. There was no significant difference in nonrelapse mortality between recipients with and without del(Y) (HR, 1.08; 95% CI, 0.769-1.51; P = .67). In contrast, del(Y) was not significantly associated with any clinical outcomes in the cohort of male-to-male allo-HCT. A higher incidence of relapse might have been caused by attenuation of the GVL effect resulting from a lack of H-Y antigens. Because a GVL effect resulting from sex mismatch may not be expected in men with del(Y) who undergo allo-HCT with a female donor, additional post-allo-HCT strategies might be required to prevent disease relapse.2022年03月, Blood advances, 6(6) (6), 1895 - 1903, 英語, 国際誌研究論文（学術雑誌）
- Patients who have undergone hematopoietic stem cell transplantation (HSCT) for hematological disease experience high mortality when infected by coronavirus disease 2019 (COVID-19). However, the safety and efficacy of the COVID-19 vaccine in HSCT patients remain to be investigated. We prospectively evaluated the safety and immunogenicity of the BNT162b2 mRNA COVID-19 vaccine (Pfizer BioNTech) in 25 Japanese allogeneic HSCT patients in comparison with 19 healthy volunteers. While anti-S1 antibody titers in almost all healthy volunteers after the second dose were higher than the cut-off value reported previously, levels in HSCT patients after the second dose were diverse. Nineteen patients (76%) had seroconversion of anti-S1 IgG. The median optical density of antibody levels in HSCT patients with low IgG levels (<600 mg/dL), steroid treatment, or low lymphocytes (<1000/μL) was significantly lower than that in the other HSCT patients. There were no serious adverse events (>Grade 3) and no new development or exacerbation of graft-versus-host disease after vaccination. We concluded that the BNT162b2 mRNA vaccine is safe and effective in Japanese allogeneic HSCT patients.2022年01月, Vaccines, 10(2) (2), 英語, 国際誌研究論文（学術雑誌）
- We investigated the efficacy of BNT162b2 mRNA COVID-19 vaccine in patients with B-cell malignancies treated with anti-CD20 antibody. Although T-cell-mediated immune responses were detected even in patients receiving R-CHOP treatment, the S1 antibody titer following BNT162b2 vaccination remained only marginally increased for more than 3 years after the final dose of anti-CD20 antibody. We found no relationship between the percent of B-cells and S1 antibody titer. The duration of this suppression was much longer than we anticipated. Further protection and treatment strategies against COVID-19 for these patients are warranted.2022年01月, International journal of hematology, 115(1) (1), 7 - 10, 英語, 国内誌研究論文（学術雑誌）
- (一社)日本神経学会, 2021年12月, 臨床神経学, 61(12) (12), 885 - 885, 日本語5年の経過で再発・寛解を繰り返しCLIPPERSが先行してT細胞リンパ腫と診断した一例
- Serum Cytokine Profiles of Rapid Recovery Patients with COVID-19: Series of 6 Cases.COVID-19 patients reveal various clinical manifestations; however, the specific mechanisms and factors contributing to rapid recovery remain unclear. We performed serum cytokine profiling using a bead-based immunoassay in six COVID-19 patients with mild symptoms who experienced rapid recovery. All patients had fever that resolved within 4 days. During the study, the interferon gamma-related protein 10 (IP-10) level rapidly increased initially, and then rapidly decreased in all six patients. Similarly, the interferon (IFN)-λ 2/3 levels rapidly increased initially, and then decreased in five of the six patients. IP-10 and IFN-λ2/3 may play a key role in the rapid recovery of mild COVID-19.2021年10月, The Kobe journal of medical sciences, 67(2) (2), E55-E60, 英語, 国内誌[査読有り]研究論文（学術雑誌）
- 2021年09月, International journal of laboratory hematology, 英語, 国際誌
- (一社)日本血液学会, 2021年09月, 日本血液学会学術集会, 83回, PS - 7, 英語NRAS c.38G>A変異により発症したRARAの相互転座を伴わない急性前骨髄球性白血病(Novel NRAS c.38G>A mutation causes RARA translocation negative acute promyelocytic-like leukemia)
- (一社)日本血液学会, 2021年09月, 日本血液学会学術集会, 83回, PS - 2, 英語新たなKMT2A/EPS15融合遺伝子発現とt(1;11)(p32;q23)転座を認めたFLT3変異陽性B細胞性急性リンパ性白血病(Expression of a novel KMT2A/EPS15 fusion gene in FLT3 mutation-positive B-ALL with t(1;11)(p32;q23))
- (一社)日本血液学会, 2021年09月, 日本血液学会学術集会, 83回, PS - 6, 英語慢性GVHDに対する肝移植後の一過性末梢血マクロキメリズム(Transient macrochimerism following a liver transplant for hepatic GVHD after an allo-PBSCT)
- (一社)日本血液学会, 2021年09月, 日本血液学会学術集会, 83回, OS2 - 4, 英語自家造血幹細胞移植患者におけるsynbiotics投与の有効性についての臨床試験(Efficacy of synbiotics in auto-PBSCT patients: a prospective, double-blind, placebo-controlled trial)
- (一社)日本血液学会, 2021年09月, 日本血液学会学術集会, 83回, OS3 - 5, 英語同種移植におけるflash sensor-based glucose monitoringの安全性の検討(Safety and accuracy of flash sensor-based glucose monitoring devise in patients after Allo-HSCT)
- Although graft failure (GF) is a fatal complication after allogeneic stem cell transplantation (SCT), no mortality risk assessments after salvage SCT have been reported. We developed a comprehensive prognostic scoring system consisting of patient and comorbidity factors with 470 patients as a training cohort out of 940; these patients underwent salvage SCT for GF. The multivariate analysis demonstrated that older age, poorer performance status, a continuation of antimicrobial treatment, and severe organ dysfunction were independently associated with worse overall survival (OS) and non-relapse mortality (NRM). Based on each factor's hazard ratio, weighted scores of 1-3 were assigned to these factors. Using the summed scores (0-8), a prognostic scoring system successfully stratified outcomes after salvage SCT in the cohort. For patients in the low (0-2, n = 122), intermediate (3-4, n = 209), and high score (5-8, n = 110) groups, the 1-year OS was 62.8%, 40.8%, and 14.2%, respectively (P < 0.001), whereas the 1-year NRM was 24.1%, 43.9%, and 72.7%, respectively (P < 0.001). The prognostic value of the scoring system was confirmed in the validation cohort (n = 470). Our scoring system is useful for predicting survival after salvage SCT.2021年09月, Bone marrow transplantation, 56(9) (9), 2183 - 2193, 英語, 国際誌研究論文（学術雑誌）
- Background: Antibody production is one of the primary mechanisms for recovery from coronavirus disease 2019 (COVID-19). It is speculated that massive clonal expansion of B cells, which can produce clinically meaningful neutralizing antibodies, occurs in patients who recover on the timing of acquiring adaptive immunity. Methods: To evaluate fluctuations in clonal B cells and the size of the clones, we chronologically assessed the B-cell receptor (BCR) repertoire in three patients with COVID-19 who recovered around 10 days after symptom onset. Results: We focused on the three dominant clonotypes (top 3) in each individual. The percentage frequencies of the top 3 clonotypes increased rapidly and accounted for 27.8 % on day 9 in patient 1, 10.4 % on day 12 in patient 2, and 10.8 % on day 11 in patient 3, respectively. The frequencies of these top 3 clonotypes rapidly decreased as the patients' clinical symptoms improved. Furthermore, BCR network analysis revealed that accumulation of clusters composed of similar complementarity-determining region 3 (CDR3) sequences were rapidly formed, grew, and reached their maximum size around 10 days after symptom onset. Conclusions: BCR repertoire analysis revealed that a massive surge of some unique BCRs occurs during the acquisition of adaptive immunity and recovery. The peaks were more prominent than expected. These results provide insight into the important role of BCRs in the recovery from COVID-19 and raise the possibility of developing neutralizing antibodies as COVID-19 immunotherapy.2021年08月, Heliyon, 7(8) (8), e07748, 英語, 国際誌研究論文（学術雑誌）
- Elsevier BV, 2021年06月, Cancer Genetics, 254-255, 92 - 97研究論文（学術雑誌）
- Springer Science and Business Media LLC, 2021年03月, SN Comprehensive Clinical Medicine, 3(6) (6), 1455 - 1462研究論文（学術雑誌）
- Regorafenib is an oral multi-kinase inhibitor which targets tumor angiogenesis, the tumor microenvironment and oncogenesis. Based on this mode of action, regorafenib has a broad spectrum of toxicities. However, at present, few reports have focused on autoimmune adverse events. We report a first case of regorafenib-induced exacerbation of chronic immune thrombocytopenic purpura in remission during treatment for the patients with heavily treated advanced colorectal cancer. This case report highlights the need for caution with regard to regorafenib treatment in patients with cancer with concomitant immune thrombocytopenic purpura.2021年02月, Molecular and clinical oncology, 14(2) (2), 30 - 30, 英語, 国際誌研究論文（学術雑誌）
- BACKGROUND/AIM: Biomarkers for immune-related adverse events (irAEs) induced by immune checkpoint inhibitors (ICIs) are required. We encountered a patient whose skin irAE fluctuated in parallel with serum soluble interleukin-2 receptor (sIL-2R). PATIENTS AND METHODS: We examined 15 patients with cancer who received ICIs. Serum sIL-2R levels before and during ICI treatment were measured. The sIL-2R levels of preserved serum samples from another five patients who developed grade 3 irAEs were measured. RESULTS: Twelve patients showed no significant changes in sIL-2R levels during ICI treatment. Baseline serum sIL-2R levels in three patients increased beyond the normal range before the second cycle. These three patients had grade ≥2 irAEs at the second cycle treatment visit, supporting our hypothesis. Furthermore, at diagnosis of irAEs, the sIL-2R levels of all preserved samples from patients with grade 3 irAEs were significantly elevated. CONCLUSION: Serum sIL-2R is a promising biomarker for the diagnosis of irAEs.2021年02月, Anticancer research, 41(2) (2), 1021 - 1026, 英語, 国際誌研究論文（学術雑誌）
- Springer Science and Business Media LLC, 2020年12月, International Journal of Hematology, 112(6) (6), 864 - 870研究論文（学術雑誌）
- Elsevier BV, 2020年11月, Journal of Infection and Chemotherapy, 26(11) (11), 1216 - 1219研究論文（学術雑誌）
- (一社)日本循環器学会, 2020年07月, 日本循環器学会学術集会抄録集, 84回, PE52 - 6, 英語Bleeding Events Associated with Anticoagulant Therapy; Apixaban in Japanese Patients with Cancer-associated Venous Thromboembolism: A Multicenter Phase II Trial(J-CAV)(和訳中)
- (一社)日本医学教育学会, 2020年07月, 医学教育, 51(Suppl.) (Suppl.), 105 - 105, 日本語
- Elsevier BV, 2020年04月, Cancer Genetics, 242, 35 - 40研究論文（学術雑誌）
- Acute myeloid leukemia (AML) with an inv(16)(p13q22) or t(16;16)(p13;q22) chromosomal abnormality represents one of the most common subtypes of de novo cases. These chromosomal rearrangements result in multiple CBFB-MYH11 fusion transcripts, with type-A being the most frequent. We here describe a unique case of de novo AML-M1, with inv(16)(p13q22), leading to an unusual CBFB-MYH11 fusion transcript, and der(7)t(7;11)(q31;q21). The fusion transcript involves a CBFB exon 5 with a breakpoint at nucleotide 754, an insertion of a 13-bp sequence of CBFB intron 5 at the fusion point, and the MYH11 exon 27 with a breakpoint at nucleotide 3464. To our knowledge, this CBFB-MYH11 fusion transcript has never been reported previously. The clinical characteristics of the present case are in line with previous reports suggesting that rare CBFB-MYH11 fusion transcripts lead to aberrant characteristics such as an atypical cytomorphology and additional cytogenetic abnormalities.2020年02月, Cancer genetics, 241, 72 - 76, 英語, 国際誌[査読有り]
- OBJECTIVE: Chemotherapy-induced peripheral neuropathy (CIPN) is a common adverse event experienced by cancer patients. In general, CIPN is evaluated subjectively based on patient self-assessment or clinician-reported scales; evidence supporting the utility and validity of quantitative sensory tests (QST) is lacking in this patient population. The aim of this study was to objectively assess CIPN of lower extremities by QSTs, and to evaluate the concordance between QSTs and subjective assessments. METHODS: In this prospective cohort study, outpatients with cancer receiving chemotherapy were recruited at a single university hospital. We assessed CIPN at the lower extremities at baseline and three months after baseline. The QSTs were performed by applying a monofilament and a tuning fork to determine touch and vibration thresholds, respectively, at the affected site. Subjective assessments were performed based on the visual analog scale (VAS) and the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) toxicity grade. Kappa coefficients were calculated to evaluate the concordance between QSTs and subjective assessments. RESULTS: After exclusion and drop-outs during follow-up, nineteen patients were included in the analysis. The prevalence of patients with abnormal sensation was 37% based on QSTs, 32% based on the VAS, and 14% based on CTCAE grading, respectively. Kappa coefficients were 0.32 between QSTs and VAS, and 0.28 between QSTs and CTCAE. CONCLUSIONS: The concordance rates between quantitative and subjective assessments were low. CIPN should be assessed using both quantitative and subjective assessments.2020年, Physical therapy research, 23(2) (2), 166 - 171, 英語, 国内誌[査読有り]研究論文（学術雑誌）
- Springer Science and Business Media LLC, 2019年11月, International Journal of Hematology, 110(5) (5), 521 - 523研究論文（学術雑誌）
- 2019年10月, International journal of hematology, 110(4) (4), 490 - 499[査読有り]
- Springer Science and Business Media LLC, 2019年07月, International Journal of Hematology, 110(1) (1), 107 - 114研究論文（学術雑誌）
- The use of granulocyte colony-stimulating factor-mobilized peripheral blood stem cells (PBSCs) and sex-mismatched hematopoietic cell transplantation (HCT), especially with female donors and male recipients (FtoM), is known to be associated with an increased risk of chronic graft-versus-host disease (GVHD) compared with transplantation with bone marrow (BM). This raises the question of whether the use of PBSCs in FtoM HCT might affect allogeneic responses, resulting in fatal complications. Using a Japanese transplantation registry database, we analyzed 1132 patients (FtoM, n = 315; MtoF, n = 260; sex-matched, n = 557) with standard-risk diseases who underwent HCT with an HLA-matched related donor without in vivo T-cell depletion between 2013 and 2016. The impact of PBSC vs BM on transplantation outcomes was separately assessed in FtoM, MtoF, and sex-matched HCT. Overall survival (OS) and nonrelapse mortality (NRM) at 2 years post-HCT were significantly worse in patients with PBSCs vs those with BM in FtoM HCT (2-year OS, 76% vs 62%; P = .0084; 2-year NRM, 10% vs 21%; P = .0078); no differences were observed for MtoF or sex-matched HCT. Multivariate analyses confirmed the adverse impact of PBSCs in FtoM HCT (hazard ratio [HR] for OS, 1.91; P = .025; HR for NRM, 3.70; P = .0065). In FtoM HCT, patients with PBSCs frequently experienced fatal GVHD and organ failure. In conclusion, the use of PBSCs in FtoM HCT was associated with an increased risk of NRM in the early phase, resulting in inferior survival. This suggests that, when we use female-related donors for male patients in HCT, BM may result in better outcomes than PBSCs.2019年06月, Blood advances, 3(11) (11), 1750 - 1760, 英語, 国際誌[査読有り]研究論文（学術雑誌）
- Sinusoidal obstruction syndrome (SOS) is a lethal complication after hematopoietic stem cell transplantation (HSCT). Defibrotide (DF) is the only drug internationally recommended for SOS treatment in Western countries. Recombinant human soluble thrombomodulin (rhTM), which is promising for the treatment of patients with disseminated intravascular coagulation, is also reported to be potentially effective for SOS. To clarify the safety and efficacy of DF and rhTM, we conducted a retrospective survey of these agents in Japan. Data from 65 patients who underwent allogeneic HSCT and received DF (n = 24) or rhTM (n = 41) for SOS treatment were collected. The complete response rates for SOS on day 100 were 50% and 54% in the DF and rhTM groups, respectively. The 100-day overall survival rates were 50% in the DF group, and 48% in the rhTM group. Several severe hemorrhagic adverse events were observed in one patient in the DF group and five patients in the rhTM group. The main causes of death were SOS-related death, and no patient died of direct adverse events of DF or rhTM. Our results suggest that rhTM, as well as DF, can be effective as a novel treatment option for SOS.2019年05月, Bone marrow transplantation, 54(5) (5), 674 - 680, 英語, 国際誌[査読有り]研究論文（学術雑誌）
- Chemotherapy-induced peripheral neuropathy (CIPN) frequently occurs in lymphoma patients receiving R-CHOP, a drug combination therapy. Although severe CIPN may lead to reduction and/or discontinuation of the medication, predictive factors of CIPN have not been investigated sufficiently to date. We performed a retrospective exploratory research to determine associations between prevalence of severe CIPN and sociodemographic data, health characteristics, and medical conditions such as anemia at initial diagnosis. Forty patients (indolent lymphoma, n = 9; diffuse large B-cell lymphoma; n = 31) received R-CHOP therapy from September 2009 to July 2014. The median age of patients was 58 years (range = 27-76 years). Statistical analyses were applied to the patients, who were divided into two groups: mild CIPN (no symptoms or grade 1 according to the CTCAE version 3.0 program) and severe CIPN patients (grade 2 or higher). Forward stepwise logistic regression analyses were performed using the following variables: sex, BMI, BSA, hyperglycemia, malnutrition, and anemia. Severe CIPN occurred in seven patients (17.5%). Gender and anemia remained following the stepwise procedure, and anemia predicted severe CIPN significantly (OR = 19.45, 95% confidence interval = 1.52-171.12). Our study suggests that anemia at initial diagnosis could be a predictive factor of R-CHOP-induced CIPN.2019年03月, Oncology research, 27(4) (4), 469 - 474, 英語, 国際誌[査読有り]研究論文（学術雑誌）
- A 45-year-old woman was diagnosed with hepatosplenic T-cell lymphoma (HSTCL), a rare subtype of peripheral T-cell lymphoma. She received different types of chemotherapy, but disease progression was observed. To reduce the tumor burden before an unrelated bone marrow transplantation, combination chemotherapy consisting of the gemcitabine, carboplatin, and dexamethasone (GCD) was administered as bridging therapy, resulting in a reduction in the number of lymphoma cells. We were then able to perform bone marrow transplantation. Although she experienced some adverse events, she successfully achieved long-term remission. We herein report a successful case of HSTCL treated with unrelated stem cell transplantation following the GCD regimen as bridging chemotherapy.2019年03月, Intern Med., 58(5) (5), 707 - 712, 英語, 国内誌[査読有り]研究論文（学術雑誌）
- BACKGROUND: Human herpesvirus 6 (HHV-6) encephalitis is a known life-threatening complication following allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, few studies have focused on the occurrence of HHV-6 encephalitis in patients receiving mycophenolate mofetil (MMF) combined with a calcineurin inhibitor as prophylaxis for graft-versus-host disease (GVHD). This study aimed to investigate the impact of MMF administered for GVHD prophylaxis in the occurrence of HHV-6 encephalitis after allo-HSCT and the characteristics of this condition. METHODS AND RESULTS: We retrospectively analyzed 73 patients who underwent allo-HSCT (83 transplants) at our hospital between April 2010 and December 2015. MMF (2-3 g/d) was administered along with a calcineurin inhibitor. Seven patients (8.0%) developed encephalitis due to HHV-6. The median period from allo-HSCT to the onset of HHV-6 encephalitis was 23 days (range, 17-98 days). The cumulative incidence of HHV-6 encephalitis on day 100 after treatment was 12% and 6% in patients who underwent cord blood transplantation (CBT) and non-CBT (ie, bone marrow transplantation and peripheral blood stem cell transplantation), respectively (P = 0.344). Neurological symptoms of encephalitis were more severe in non-CBT cases than those in CBT cases. All patients diagnosed with HHV-6 encephalitis were treated with ganciclovir or foscarnet. None of the enrolled patients died from HHV-6 encephalitis. CONCLUSIONS: Mycophenolate mofetil may have the potential to increase the frequency of severe HHV-6 encephalitis in patients undergoing CBT and non-CBT. Thus, MMF should be administered with caution, and patients should be monitored closely for HHV-6 encephalitis even those who did not undergo CBT.2019年02月, Transpl Infect Dis., 21(1) (1), e13024, 英語, 国際誌[査読有り]研究論文（学術雑誌）
- (一社)日本血液学会-東京事務局, 2019年01月, 臨床血液, 60(1) (1), 59 - 59, 日本語PET/MRI陰性だが頭部造影MRIにて中枢神経浸潤が明らかとなった精巣原発DLBCLの1例
- Scopulariopsis alboflavescens is a soil saprophyte that is widely distributed in nature. Recently, there have been increasing number of reports of invasive infections with Scopulariopsis species in immunocompromised patients. In this report, we described an adult woman with acute myeloid leukemia and who developed S. alboflavescens pneumonia. Liposomal amphotericin B and voriconazole combination therapy was unsuccessful and the patient died because of pneumonia. Scopulariopsis is highly resistant to available antifungal agents and almost invariably fatal. This case report should alert clinicians to the importance of listing Scopulariopsis as a pathogenic fungus in immunocompromised patients.2018年12月, Int J Hematol., 108(6) (6), 658 - 664, 英語, 国内誌[査読有り]研究論文（学術雑誌）
- A 69-year-old woman who had been diagnosed with unresectable papillary thyroid cancer was referred to our hospital. We initially treated her with sorafenib, but she subsequently developed erythema multiforme, which was suspected to be a drug rush due to sorafenib; therefore, sorafenib was discontinued. At the time of discontinuation, immature blast cells were detected in her peripheral blood. Approximately two weeks later, her skin rash improved substantially, but the proportion of blasts in the peripheral blood increased. We performed a bone marrow examination, and she was diagnosed with FLT3-ITD-positive acute myeloid leukemia. FLT3-ITD expression is found in 20-25% of AML and is a known independent poor prognostic factor. To overcome the poor prognosis associated with FLT3-ITD, molecular drugs targeting FLT3-ITD are attracting much attention. Sorafenib, a multi-kinase inhibitor, also has an effect on FLT3-ITD. Although primary disease flares after tyrosine kinase inhibitor discontinuation have been reported, this is the first report to describe discontinuation of sorafenib treatment as a potential trigger of FLT3-ITD-positive acute myeloid leukemia in papillary thyroid cancer.2018年12月, J Oncol Pharm Pract, 25(8) (8), 2010 - 2015, 英語, 国際誌[査読有り]研究論文（学術雑誌）
- PURPOSE: The purpose of this study was to measure the frequency and identify factors associated with delayed socket healing after dental extraction in patients undergoing myelosuppressive chemotherapy for hematologic malignancy. MATERIALS AND METHODS: This prospective cohort study focused on delayed healing after extraction in patients with hematologic malignancy. Sockets with delayed healing were defined as those with intense pain and bone exposure 1 week postoperatively. Patients with and without delayed socket healing were compared using the Fisher exact test and Mann-Whitney U test with some variables. Receiver operating characteristics curve analysis was conducted to define cutoff values for delayed healing. RESULTS: One hundred ninety-four dental extractions in 93 patients (median age, 64 yr; range, 20 to 85 yr) were analyzed. The incidence of delayed socket healing was 7.5% (7 of 93 patients). There was no postoperative bleeding. Older age, type of hematologic malignancy (acute leukemia), shorter time from dental extraction to initiation of chemotherapy, low platelet count or hemoglobin level, requirement for red blood cell concentrate or platelet transfusion, and use of an absorbable hemostatic agent were statistically associated with the occurrence of delayed socket healing. Platelet and hemoglobin cutoffs were 4.6 × 104/μL and 7.7 g/dL, respectively. CONCLUSIONS: Although dental extraction can be safely performed in patients undergoing myelosuppressive chemotherapy for hematologic malignancy, oral surgeons should understand the potential risk for delayed socket healing. When considering dental extraction, patients with hematologic malignancy and low hemoglobin or platelet levels should be informed about the possibility of delayed socket healing.2018年10月, J Oral Maxillofac Surg, 76(10) (10), 2057 - 2065, 英語, 国際誌[査読有り]研究論文（学術雑誌）
- (一社)日本血液学会-東京事務局, 2018年09月, 臨床血液, 59(9) (9), 1641 - 1641, 英語sorafenib投薬を中断することで顕在化したFLT3-ITD陽性急性骨髄性白血病の一例(Discontinuation of sorafenib can lead to the emergence of FLT3-ITD-positive acute myeloid leukemia)
- (一社)日本血液学会-東京事務局, 2018年09月, 臨床血液, 59(9) (9), 1733 - 1733, 英語多発性筋炎様症状を呈したNK/T細胞リンパ腫(Extranodal NK/T-cell lymphoma mimicking polymyositis)
- (一社)日本血液学会-東京事務局, 2018年09月, 臨床血液, 59(9) (9), 1756 - 1756, 英語TLR9の一塩基多型により無症候性CMV感染症を呈した再生不良性貧血の一例(Aplastic anemia that developed asymptomatic CMV infection due to SNPs of TLR9)
- (一社)日本血液学会-東京事務局, 2018年09月, 臨床血液, 59(9) (9), 1815 - 1815, 英語シクロスポリン療法後の骨髄移植にて重症肝類洞閉塞症候群をきたした一例(Severe sinusoidal obstruction syndrome after cyclosporine treatment followed by transplantation)
- (一社)日本血液学会-東京事務局, 2018年09月, 臨床血液, 59(9) (9), 1640 - 1640, 英語新たなZMYND11/MBTD1融合遺伝子の発現とt(10;17)(p15;q21)転座を認めたCD7+CD56+急性骨髄性白血病(Expression of a novel ZMYND11/MBTD1 fusion transcript in CD7+CD56+ AML with t(10;17)(p15;q21))[査読有り]
- Springer Science and Business Media LLC, 2018年07月, International Journal of Hematology, 108(1) (1), 58 - 65研究論文（学術雑誌）
- BACKGROUND: CD134 (OX40), which is a cellular receptor for human herpesvirus-6B (HHV-6B) and expresses on activated T cells, may play a key role for HHV-6B replication after allogeneic hematopoietic stem cell transplantation (allo-HSCT). OBJECTIVES: Therefore, we examined the CD134 expression on T cells and HHV-6B replication after allo-HSCT, and analyzed the correlation between them. STUDY DESIGN: Twenty-three patients after allo-HSCT were enrolled. The percentages of CD134-positive cells within the CD4+ and CD8+ cell populations were measured by flow cytometry, and the viral copy number of HHV-6B was simultaneously quantified by real-time PCR. The correlation between CD134 and HHV-6B viral load was then statistically analyzed. RESULTS: HHV-6B reactivation occurred in 11 of 23 patients (47.8%). CD134 expression was seen on T cells and was coincident with the time of peak viral load. The percentage of CD134-positive cells decreased significantly when HHV-6B DNA disappeared (p = .005 in CD4+ T cells, p = .02 in CD8+ T cells). In the 4 patients who underwent umbilical cord blood transplantation (UCBT), the viral load varied with the percentage of CD134-positive cells. In the comparison between the HHV-6B reactivation group and non-reactivation group, maximum percentages of CD134-positive cells among CD4+ T cells in reactivation group were significantly higher than those in non-reactivation group (p = .04). CONCLUSIONS: This is the first study to show that a correlation of CD134 expression on T cells with HHV-6B replication after allo-HSCT, especially in UCBT. The results possibly indicate that CD134 on T cells plays a key role for HHV-6B replication after allo-HSCT.2018年05月, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 102, 50 - 55, 英語, 国際誌[査読有り]研究論文（学術雑誌）
- PURPOSE: Mycophenolate mofetil (MMF) is increasingly used among Japanese patients undergoing allogeneic hematopoietic stem cell transplantation (allo-SCT). Because pharmacokinetic data for MMF in the Asian population are limited, we conducted this investigation. METHODS: Intravenous MMF (1000 mg/dose) was administered to 10 patients along with cyclosporine or tacrolimus for 10 days after allo-SCT; it was administered every 8 h in peripheral blood stem cell- and bone marrow-transplanted patients, and every 12 h in cord blood-transplanted patients. MMF was administered orally at the same dose from day 11. Plasma concentrations of mycophenolic acid (MPA) were measured by high-performance liquid chromatography. RESULTS: The MPA AUC0 - tau was 31.9 ± 3.4, 26.2 ± 2.4, and 21.0 ± 2.2 µg*h/mL, the mean Ctrough was 0.25, 0.35, and 0.37 µg/mL, and the Cmax was 10.8, 9.2, and 5.5 µg/mL on days 2, 9, and 16, respectively. The AUC0 - tau and Cmax were significantly higher after intravenous MMF dosing than after oral MMF dosing. All patients exhibited successful neutrophil engraftments in a median time of 18 days. Grade II acute graft-versus-host disease (GvHD) of the skin was observed in two patients, and one patient developed limited chronic GvHD. Individual cases of transient and curable grade III oral mucositis and diarrhea were observed; however, MMF was not discontinued. No other severe complications or infections were observed. CONCLUSIONS: Intravenously administered MMF was safe and possibly effective in achieving higher MPA plasma concentrations for GvHD prophylaxis after allo-SCT in Japanese patients.2018年03月, Cancer Chemother Pharmacol, 81(5) (5), 839 - 846, 英語, 国際誌[査読有り]研究論文（学術雑誌）
- Lymph node infarction is very rare, and is frequently associated with neoplasms, such as malignant lymphoma and non-neoplastic disease, or interventions such as fine-needle aspiration (FNA). A 76-year-old-man presented with cervical lymph node swelling. Although FNA was performed, the findings were insufficient for a definitive diagnosis. Consequently, surgical biopsy of the cervical lymph node was performed, which revealed total infarction; a diagnosis of classical Hodgkin lymphoma was made later. Both lymphoma itself and FNA may cause total lymph node infarction, which makes diagnosis confusing. Therefore, it is important to repeat the biopsy rather than repeat FNA to correctly diagnose malignant lymphoma, including Hodgkin lymphoma.2018年03月, J Clin Exp Hematop., 58(1) (1), 24 - 26, 英語, 国内誌[査読有り]研究論文（学術雑誌）
- S. Karger AG, 2018年02月, Cytogenetic and Genome Research, 153(3) (3), 131 - 137, 英語[査読有り]研究論文（学術雑誌）
- Springer Tokyo, 2018年01月, International Journal of Hematology, 107(1) (1), 83 - 91, 英語[査読有り]研究論文（学術雑誌）
- 2017年12月, INTERNATIONAL JOURNAL OF HEMATOLOGY, 106(6) (6), 729 - 731, 英語[査読有り]研究論文（学術雑誌）
- (一社)日本血液学会-東京事務局, 2017年11月, 臨床血液, 58(11) (11), 2289 - 2289, 日本語慢性C型肝炎治療後に発症したB細胞性前リンパ球性白血病の1例
- 2017年11月, Clin Nutr, 英語A multi-center prospective study randomizing the use of fat emulsion in intensive glucose control after allogeneic hematopoietic stem cell transplantation using a myeloablative conditioning regimen[査読有り]研究論文（学術雑誌）
- (一社)日本血液学会-東京事務局, 2017年09月, 臨床血液, 58(9) (9), 1763 - 1763, 日本語悪性リンパ腫患者におけるコリンエステラーゼ値層別化による腫瘍崩壊症候群発症リスクの後方視的解析
- 2017年07月, PLOS ONE, 12(7) (7), e0182021, 英語[査読有り]研究論文（学術雑誌）
- 2017年04月, INTERNATIONAL JOURNAL OF HEMATOLOGY, 105(4) (4), 485 - 496, 英語[査読有り]研究論文（学術雑誌）
- MDPI AG, 2017年03月, International Journal of Molecular Sciences, 18(3) (3), 英語[査読有り]研究論文（学術雑誌）
- 2017年02月, AMERICAN JOURNAL OF HEMATOLOGY, 92(2) (2), 171 - 178, 英語[査読有り]研究論文（学術雑誌）
- 2017年02月, INTERNATIONAL JOURNAL OF HEMATOLOGY, 105(2) (2), 226 - 229, 英語[査読有り]研究論文（学術雑誌）
- 一般社団法人 日本血液学会, 2017年, 臨床血液, 58(8) (8), 938 - 941, 日本語
A 49-year-old female was initially diagnosed with acute myeloid leukemia (AML) M4 with a CD45＋CD13＋CD33＋CD34−HLA-DR＋ immunophenotype. She underwent allogeneic bone marrow transplantation, but the disease recurred. The bone marrow was infiltrated with 87.0% blasts negative for myeloperoxidase (MPO) staining. Immunophenotyping by flow cytometry identified the presence of a CD45-negative blast population. These blasts exhibited a CD13＋CD33＋CD19−CD10−CD34−HLA-DR− immunophenotype. The lack of CD45 expression is often observed in B-cell acute lymphoblastic leukemia, whereas CD45-negative AML is extremely rare; only one older male with AML-M0 has been reported. In the present case, the CD45-negative blasts had an MPO−CD13＋CD33＋ phenotype, which is similar to AML-M0.
- 2016年12月, INTERNATIONAL JOURNAL OF HEMATOLOGY, 104(6) (6), 682 - 691, 英語[査読有り]研究論文（学術雑誌）
- This retrospective study was conducted in Japan to determine the incidence, risk factors and outcomes of sinusoidal obstruction syndrome (SOS) after allogeneic hematopoietic stem cell transplantation (HSCT). Among 4290 patients undergoing allogeneic HSCT between 1999 and 2010, 462 were diagnosed with SOS according to the Seattle criteria (cumulative incidence, 10.8%). The cumulative incidence of SOS diagnosed by the modified Seattle criteria was 9.3%. Of 462 patients, 107 met the Baltimore criteria and 168 had severe SOS with renal and/or respiratory failure. The median onset for SOS was 12 days after HSCT (range, -2-30). Overall survival at day 100 was 32% for SOS and 15% for severe SOS. Multivariate analyses showed that significant independent risk factors for SOS were the number of HSCTs, age, performance status, hepatitis C virus-seropositivity, advanced disease status and myeloablative regimen. SOS was highly associated with overall mortality (hazard ratio, 2.09; P<0.001). Our retrospective survey showed that the cumulative incidence of SOS in Japan was 10.8%, similar to that previously reported in Western countries, and that the overall survival of patients who developed SOS2016年03月, Bone Marrow Transplant, 51(3) (3), 403 - 9, 英語
- 2016年03月, BONE MARROW TRANSPLANTATION, 51(3) (3), 403 - 409, 英語[査読有り]研究論文（学術雑誌）
- 2016年, Cytogenetic and Genome Research, 150(3-4) (3-4), 287 - 292研究論文（学術雑誌）
- 2016年, CYTOGENETIC AND GENOME RESEARCH, 150(3-4) (3-4), 287 - 292, 英語[査読有り]研究論文（学術雑誌）
- 2016年, Bone Marrow Transplantation, 51, S411Absolute Lymphocyte Count Recovery Predicts Clinical Outcome after Allogeneic Hematopoietic Stem Cell Transplantation in a Japanese Population[査読有り]
- 2016年, CYTOGENETIC AND GENOME RESEARCH, 149(3) (3), 165 - 170, 英語[査読有り]研究論文（学術雑誌）
- Oxford University Press, 2016年, Japanese Journal of Clinical Oncology, 46(5) (5), 448 - 452, 英語[査読有り]研究論文（学術雑誌）
- 2015年12月, INTERNATIONAL JOURNAL OF HEMATOLOGY, 102(6) (6), 713 - 718, 英語[査読有り]研究論文（学術雑誌）
- Taylor and Francis Ltd, 2015年11月, Leukemia and Lymphoma, 56(11) (11), 3045 - 3051, 英語[査読有り]研究論文（学術雑誌）
- 2015年11月, LEUKEMIA & LYMPHOMA, 56(11) (11), 3045 - 3051, 英語[査読有り]研究論文（学術雑誌）
- Oxford University Press ({OUP}), 2015年10月, Ann Oncol, 26(suppl 7) (suppl 7), vii85.1[査読有り]
- 2015年05月, Transpl Int, 英語[査読有り]研究論文（学術雑誌）
- Springer-Verlag Tokyo, 2015年05月, International Journal of Hematology, 101(5) (5), 423 - 425, 英語研究論文（その他学術会議資料等）
- 2015年02月, JOURNAL OF DENTAL RESEARCH, 94(2) (2), 289 - 296, 英語[査読有り]研究論文（学術雑誌）
- 2015年, J Clin Exp Hematop, 55(3) (3), 181 - 5, 英語Coexistent t(8;21)(q22;q22) Translocation and 5q Deletion in Acute Myeloid Leukemia[査読有り]研究論文（学術雑誌）
- 2015年, ACTA HAEMATOLOGICA, 134(2) (2), 76 - 79, 英語[査読有り]研究論文（学術雑誌）
- 2015年01月, BONE MARROW TRANSPLANTATION, 50(1) (1), 100 - 105, 英語[査読有り]研究論文（学術雑誌）
- 2015年01月, ANNALS OF HEMATOLOGY, 94(1) (1), 177 - 179, 英語[査読有り]研究論文（学術雑誌）
- 2014年08月, ANNALS OF HEMATOLOGY, 93(8) (8), 1435 - 1438, 英語[査読有り]研究論文（学術雑誌）
- 2014年03月, ANNALS OF HEMATOLOGY, 93(3) (3), 499 - 500, 英語[査読有り]研究論文（学術雑誌）
- 2014年02月, Ann Hematol, 93(10) (10), 1791 - 3, 英語, 国際誌[査読有り]研究論文（学術雑誌）
- 2014年, ACTA HAEMATOLOGICA, 132(2) (2), 244 - 246, 英語[査読有り]研究論文（学術雑誌）
- 2014年, J Clin Exp Hematop, 54(2) (2), 167 - 70, 英語, 国内誌A new complex translocation t(8;11;21)(q22;q24;q22) in acute myeloid leukemia with RUNX1/RUNX1T1[査読有り]研究論文（学術雑誌）
- 2013年12月, Annals of Hematology, 92(12) (12), 1713 - 1715, 英語[査読有り]研究論文（学術雑誌）
- 2013年11月, International Journal of Hematology, 98(5) (5), 608 - 614, 英語[査読有り]研究論文（学術雑誌）
- 2013年11月, International Journal of Hematology, 98(5) (5), 513 - 514, 英語[査読有り]研究論文（学術雑誌）
- (一社)日本癌治療学会, 2013年09月, 日本癌治療学会誌, 48(3) (3), 809 - 809, 日本語がんリハビリテーション治療の最前線 多職種チームでのがんリハビリテーションの取り組み 食道癌・造血幹細胞移植を中心に[査読有り]
- 2013年09月, Leukemia and Lymphoma, 54(9) (9), 2055 - 2058, 英語[査読有り]研究論文（学術雑誌）
- 2013年09月, Bone Marrow Transplantation, 48(9) (9), 1198 - 1204, 英語[査読有り]研究論文（学術雑誌）
- 2013年08月, BMC Oral Health, 13(1) (1), 41, 英語[査読有り]研究論文（学術雑誌）
- 2013年08月, American Journal of Hematology, 88(8) (8), 717 - 718, 英語[査読有り]研究論文（学術雑誌）
- 2013年07月, INTERNATIONAL JOURNAL OF HEMATOLOGY, 98(1) (1), 6 - 7, 英語[査読有り]研究論文（学術雑誌）
- The impact of hepatitis C virus (HCV) infection on outcomes following allogeneic hematopoietic cell transplantation (HCT) remains a matter of debate. We have retrospectively examined the significance of HCV infection among recipients who received allogeneic HCT, using a Japan transplant outcome registry database between 2006 and 2009. Among 7,831 recipients, 136 were HCV-positive. The rate of hematopoietic recovery was lower in the HCV-positive group (neutrophil recovery of 500 × 10(6) /L or higher: 79% vs. 87% at Day 30, P = 0.087; platelet recovery of 50 × 10(9) /L or higher: 57% vs. 65% at Day 60, P = 0.012). The HCV-positive group had a significantly higher incidence of nonrelapse mortality 38% vs. 25% at 2 years, P < 0.01) and inferior overall survival (41% vs. 51% at 2 years, P < 0.01). A multivariate analysis revealed that HCV seropositivity was associated with an independent risk for higher nonrelapse mortality (hazard ratio: 1.65, P < 0.01) and inferior overall survival (hazard ratio: 1.39, P < 0.01). The incidences of death due to hepatic problems (8% vs. 2%, P < 0.01), bacterial infection (10% vs. 4%, P < 0.01), or graft failure (5% vs. 2%, P = 0.084) tended to be higher in the HCV-positive group. HCV infection had an adverse impact on the clinical outcome following HCT, especially in the setting of unrelated transplantation. Careful evaluation before embarking on HCT and intensive assessment against complications are warranted in HCV-infected recipients.2013年06月, American journal of hematology, 88(6) (6), 477 - 84, 英語, 国際誌[査読有り]研究論文（学術雑誌）
- (一社)日本リンパ網内系学会, 2013年04月, 日本リンパ網内系学会会誌, 53, 109 - 109, 日本語研究論文（その他学術会議資料等）
- 2013年04月, BONE MARROW TRANSPLANTATION, 48(4) (4), 529 - 536, 英語[査読有り]研究論文（学術雑誌）
- 2013年03月, ANNALS OF HEMATOLOGY, 92(3) (3), 403 - 405, 英語[査読有り]研究論文（学術雑誌）
- (公社)日本医学放射線学会, 2013年02月, 日本医学放射線学会学術集会抄録集, 72回(72回) (72回), S402 - S402, 日本語鼻腔原発NK/T細胞リンパ腫に対する放射線治療経験[査読有り]研究論文（その他学術会議資料等）
- 2013年02月, INTERNATIONAL JOURNAL OF HEMATOLOGY, 97(2) (2), 284 - 286, 英語[査読有り]研究論文（学術雑誌）
- Gain of 11q by an additional ring chromosome 11 and trisomy 18 in CD5-positive intravascular large B-cell lymphomaChromosomal abnormalities of intravascular large B-cell lymphoma (IVLBCL), a rare form of extranodal diffuse large B-cell lymphoma, have been described in only a small number of cases. A 59-year-old female presented with pancytopenia and splenomegaly. Bone marrow was normocellular with 30.4% abnormal large lymphoid cells that were positive for CD5, CD19, CD20, HLA-DR and λ chain. Bone marrow biopsy showed intrasinusoidal infiltration of large lymphoid cells. G-banding and spectral karyotyping of the bone marrow cells demonstrated a complex karyotype as follows : 48,XX,-8,+r(11),+12,del(12)(p?) ×2,+18,der(19)(19?::p13 → qter),der(21)t(8;21)(q11.2;p11.2). Fluorescence in situ hybridization on interphase nuclei revealed three signals of CCND1 at 11q13, but two signals of BIRC3 at 11q22 and MLL at 11q23, indicating that r(11) contained CCND1. Together with other reported cases, our results indicate that the gain of 11q as well as trisomy 18 may be among the recurrent chromosomal aberrations in IVLBCL. Furthermore, an additional ring chromosome 11 could be a novel mechanism leading to the gain of 11q.2013年, J Clin Exp Hematop, 53(2) (2), 161 - 5, 英語, 国内誌[査読有り]研究論文（学術雑誌）
- 2013年01月, EUROPEAN JOURNAL OF HAEMATOLOGY, 90(1) (1), 68 - 75, 英語[査読有り]研究論文（学術雑誌）
- 2012年12月, LEUKEMIA RESEARCH, 36(12) (12), E218 - E221, 英語[査読有り]研究論文（学術雑誌）
- 日本皮膚アレルギー・接触皮膚炎学会, 2012年10月, Journal of Environmental Dermatology and Cutaneous Allergology, 6(5号) (5号), 433 - 438, 日本語多彩な神経症状を呈し、再燃時に皮疹を認めたジアフェニルスルホンによるDIHSの1例[査読有り]研究論文（学術雑誌）
- 2012年08月, AMERICAN JOURNAL OF HEMATOLOGY, 87(8) (8), 770 - 775, 英語[査読有り]研究論文（学術雑誌）
- 2012年06月, EUROPEAN JOURNAL OF HAEMATOLOGY, 88(6) (6), 553 - 554, 英語研究論文（学術雑誌）
- 2012年04月, LEUKEMIA RESEARCH, 36(4) (4), E84 - E86, 英語研究論文（学術雑誌）
- 2012年03月, EUROPEAN JOURNAL OF HAEMATOLOGY, 88(3) (3), 244 - 248, 英語研究論文（学術雑誌）
- (一社)日本血液学会-東京事務局, 2012年01月, 臨床血液, 53巻, 1号, pp. 118-119(1) (1), 118 - 119, 日本語SMILE療法及び同種骨髄移植によって良好な経過が得られた再発・難治性NK/T細胞リンパ腫の1例研究論文（国際会議プロシーディングス）
- 2011年11月, LEUKEMIA RESEARCH, 35(11) (11), E212 - E214, 英語研究論文（学術雑誌）
- 2011年09月, CANCER GENETICS, 204(9) (9), 501 - 506, 英語[査読有り]研究論文（学術雑誌）
- 2011年07月, LEUKEMIA RESEARCH, 35(7) (7), E100 - E103, 英語[査読有り]研究論文（学術雑誌）
- 2011年07月, Journal of Environmental Dermatology and Cutaneous Allergology, 5巻, 3号, pp. 263-263, 日本語皮疹を欠くもののHHV-6の再活性化と多彩な臓器症状を呈したレクチゾールによるDrug hypersensitivityの1例研究論文（国際会議プロシーディングス）
- 2011年06月, INTERNATIONAL JOURNAL OF HEMATOLOGY, 93(6) (6), 765 - 770, 英語[査読有り]研究論文（学術雑誌）
- 2011年06月, 日本検査血液学会雑誌, 12巻, 学術集会, pp. S79-S79, 日本語NPM/RARαキメラ遺伝子を認めた急性前骨髄性白血病の一例研究論文（国際会議プロシーディングス）
- 2011年06月, BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 17(6) (6), 841 - 851, 英語研究論文（学術雑誌）
- Elsevier BV, 2011年02月, Biology of Blood and Marrow Transplantation, 17, S288 - S289
- Elsevier BV, 2011年02月, Biology of Blood and Marrow Transplantation, 17, S296
- 2011年, INTERNAL MEDICINE, 50(24) (24), 3031 - 3035, 英語[査読有り]研究論文（学術雑誌）
- 2011年, INTERNAL MEDICINE, 50(8) (8), 941 - 941, 英語[査読有り]研究論文（学術雑誌）
- Elsevier BV, 2010年02月, Biology of Blood and Marrow Transplantation, 16, S254
- Elsevier {BV}, 2009年02月, Biology of Blood and Marrow Transplantation, 15(2) (2), 41[査読有り]
- 2008年07月, International journal of hematology, 88(1) (1), 104 - 10, 英語Pharmacokinetics-based optimal dose-exploration of mycophenolate mofetil in allogeneic hematopoietic stem cell transplantation[査読有り]研究論文（学術雑誌）
- 2008年05月, Cancer genetics and cytogenetics, 183(1) (1), 77 - 81, 英語Imatinib resistance in a novel translocation der(17)t(1;17)(q25;p13) with loss of TP53 but without BCR/ABL kinase domain mutation in chronic myelogenous leukemia[査読有り]研究論文（学術雑誌）
- 2007年10月, British Journal Of Haematology, 139(1) (1), 161 - 3, 英語Deregulation of a possible tumour suppressor gene, ZC3H12D, by translocation of IGK@ in transformed follicular lymphoma with t(2;6)(p12;q25)研究論文（学術雑誌）
- 2007年07月, Cancer Genetics And Cytogenetics, 176(1) (1), 61 - 6, 英語研究論文（学術雑誌）
- 2007年05月, Transplantation, 83(9) (9), 1281 - 2, 英語[査読有り]研究論文（学術雑誌）
- 2005年12月, Genes to cells : devoted to molecular & cellular mechanisms, 10(12) (12), 1127 - 1137[査読有り]
- 2005年03月, Haematologica, 90(3) (3), ECR11Cyclosporin neurotoxicity with Epstein-Barr virus-associated hemophagocytic syndrome.[査読有り]
- 2004年12月, CANCER GENETICS AND CYTOGENETICS, 155(2) (2), 154 - 155, 英語[査読有り]
- 2004年11月, CANCER GENETICS AND CYTOGENETICS, 155(1) (1), 67 - 73, 英語[査読有り]研究論文（学術雑誌）
- American Society of Hematology, 2004年04月, Blood, 103(8) (8), 2997 - 3004, 英語研究論文（学術雑誌）
- 2003年12月, HAEMATOLOGICA, 88(12) (12), 1358 - 1365, 英語Morphologic, flow cytometric and cytogenetic evaluation of bone marrow involvement in B-cell lymphoma[査読有り]研究論文（学術雑誌）
- Wiley Blackwell (Blackwell Publishing), 2002年07月, British journal of haematology, 118(1) (1), 128 - 131[査読有り]
- 2001年12月, Am J Hematol., 68(4) (4), 301 - 302, 英語[査読有り]研究論文（学術雑誌）
- 2001年12月, Ann Hematol., 80(12) (12), 749 - 751, 英語[査読有り]研究論文（学術雑誌）
- 2025年, 日本造血・免疫細胞療法学会総会プログラム・抄録集, 47thPerformance statusはSOS/VODの病勢進行予測に有用である
- 2024年, 日本造血・免疫細胞療法学会総会プログラム・抄録集, 46th類洞閉塞症候群の新改訂EBMT診断基準の有用性
- 2023年11月02日, BLOOD, 142, 英語研究発表ペーパー・要旨（国際会議）
- 2023年, 日本内科学会雑誌, 112がん関連静脈血栓塞栓症に対するアピキサバン療法の出血リスク予測:多施設共同第2相臨床試験副次的解析
- 2023年, 日本腫瘍循環器学会学術集会抄録集(Web), 6th小児がん経験者の移行期医療の現状およびがん治療歴と心機能に関する解析
- 2022年, 臨床血液, 63(2) (2)SARS-CoV-2PCRが持続陽性となったDLBCLの1症例
- 2022年, 日本造血・免疫細胞療法学会総会プログラム・抄録集, 44th同種造血幹細胞移植後患者に対するSARS-CoV-2ワクチンの安全性と有効性
- (一社)日本神経学会, 2021年12月, 臨床神経学, 61(12) (12), 885 - 885, 日本語5年の経過で再発・寛解を繰り返しCLIPPERSが先行してT細胞リンパ腫と診断した一例
- 2020年, 日本内科学会雑誌, 109リソソーム機能活性化を介した抗体薬物複合体であるゲムツズマブオゾガマイシンの殺細胞効果増強法
- 2019年05月, Leukemia & lymphoma, 60(5) (5), 1294 - 1298, 英語, 国際誌[査読有り]速報，短報，研究ノート等（学術雑誌）
- 2019年03月, 消化器・肝臓内科, 5(3) (3), 356 - 364, 日本語【薬物性肝障害:新薬登場で変わる実態】 造血幹細胞移植とSOS/VOD[招待有り]記事・総説・解説・論説等（商業誌、新聞、ウェブメディア）
- 2018年11月, Leukemia & lymphoma, 59(11) (11), 2706 - 2710, 英語, 国際誌[査読有り]速報，短報，研究ノート等（学術雑誌）
- 2017年, 日本造血細胞移植学会総会プログラム・抄録集, 40th自家末梢血幹細胞移植における栄養状態と予後に関する後方視的解析
- 2016年12月, BLOOD, 128(22) (22), 英語Impact of Total Body Irradiation on Successful Neutrophil Engraftment in Unrelated Bone Marrow or Cord Blood Transplantation研究発表ペーパー・要旨（国際会議）
- 2016年11月, INTERNATIONAL JOURNAL OF HEMATOLOGY, 104(5) (5), 531 - 533, 英語[査読有り]その他
- (公社)日本理学療法士協会, 2016年10月, 理学療法学, 43(Suppl.2) (Suppl.2), O - DM, 日本語客観的ツールで評価した化学療法誘発性末梢神経障害の経時的変化 その障害様式の調査
- 2016年07月01日, ANNALS OF ONCOLOGY, 27[査読有り]
- 2016年03月, BONE MARROW TRANSPLANTATION, 51, S77 - S78, 英語Nationwide Survey of Defbrotide and Recombinant Human Soluble Thrombomodulin for Treatment of Sinusoidal Obstruction Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation研究発表ペーパー・要旨（国際会議）
- (公社)日本医学放射線学会, 2016年02月, Japanese Journal of Radiology, 34(Suppl.) (Suppl.), 49 - 49, 日本語当院におけるゼヴァリンの初期経験[査読有り]会議報告等
- 肝中心静脈閉塞症（veno-occlusive disease，VOD）は類洞閉塞症候群（sinusoidal obstruction syndrome，SOS）としても知られており（以下SOS/VOD），造血細胞移植後合併症の一つで，重症の場合は多臓器不全を合併し80%以上の死亡率である。病態の主座は骨髄破壊的移植前処置による類洞内皮細胞の傷害と破綻による類洞閉塞である。いくつかのリスク因子に関しては知られているが，いまだ有効な予防法，治療法は確立しておらず，唯一デフィブロタイドの予防および治療効果が認められているが十分な効果とは言えない。また，臨床診断基準はほぼ確立しているが，予後評価に結び付く適切な重症度分類がなく，臨床における共通の基準が求められていた。本稿では遅発性のSOS/VODに対する診断基準と新たに導入された5段階の重症度分類について解説するとともに，国内の後方視的解析結果および現時点の治療法を中心に概説した。一般社団法人 日本造血細胞移植学会, 2016年, 日本造血細胞移植学会雑誌, 5(4) (4), 124 - 137, 日本語[招待有り]記事・総説・解説・論説等（学術雑誌）
- 2015年11月, BONE MARROW TRANSPLANTATION, 50(11) (11), 1473 - 1475, 英語[査読有り]速報，短報，研究ノート等（学術雑誌）
- メディカル・サイエンス・インターナショナル, 2015年04月, Intensivist, 7(2号) (2号), 405 - 411, 日本語【ICUで遭遇する血液疾患】(Part 2.)血液内科のクリティカルシンドローム 造血幹細胞移植に伴う重症合併症(感染症を除く) 造血幹細胞移植に伴う類洞閉塞症候群/肝中心静脈閉塞症 深刻な合併症であり,予防法・治療法の確立が求められる[査読有り]記事・総説・解説・論説等（商業誌、新聞、ウェブメディア）
- 2015年, 日本薬学会年会要旨集(CD-ROM), 135th, ROMBUNNO.26PB-AM058, 日本語造血幹細胞移植患者に対する栄養管理への介入とその評価
- 2015年, INTERNAL MEDICINE, 54(16) (16), 2057 - 2060, 英語[査読有り]速報，短報，研究ノート等（学術雑誌）
- 2015年, INTERNAL MEDICINE, 54(22) (22), 2955 - 2955, 英語[査読有り]その他
- 2014年12月, BLOOD, 124(21) (21), 英語Efficacy of the Two-Dose Influenza Vaccine in Cancer Patients Receiving Chemotherapy: A Prospective Study研究発表ペーパー・要旨（国際会議）
- (一社)日本血液学会-東京事務局, 2014年11月, 臨床血液, 55(11号) (11号), 2339 - 2339, 日本語腹部DLBCL病変出現1ヵ月前に発症したNeurolymphomatosisの1例会議報告等
- 2014年10月, ANNALS OF ONCOLOGY, 25, 英語研究発表ペーパー・要旨（国際会議）
- 2014年06月, HAEMATOLOGICA, 99, 169 - 170, 英語POOR PROGNOSIS OF PATIENTS WITH SEVERE SINUSOIDAL OBSTRUCTION SYNDROME AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN JAPANESE POPULATION: ON BEHALF OF COMPLICATIONS WORKING GROUP OF JSHCT研究発表ペーパー・要旨（国際会議）
- 2014年03月, 皮膚の科学, 12(2) (2), 143, 日本語Senile angiomaに腫瘍細胞の浸潤をみたintravascular large B-cell lymphomaの1例会議報告等
- 2014年02月14日, 日本造血細胞移植学会総会プログラム・抄録集, 36th, 238, 日本語HLA一致血縁または7‐8/8HLA一致非血縁ドナーからの同種造血細胞移植におけるMMFおよびカルシニューリン阻害剤を用いたGVHD予防の有用性:多施設共同第2相臨床試験
- 2013年11月, BLOOD, 122(21) (21), 英語Nationwide Survey of Sinusoidal Obstruction Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation: Incidence, Risk Factors, and Outcome: On Behalf of Complications Working Group of the Japan Society for Hematopoietic Cell Transplantation (JSHCT)研究発表ペーパー・要旨（国際会議）
- (一社)日本頭頸部癌学会, 2013年05月, 頭頸部癌, 39(2号) (2号), 264 - 264, 日本語鼻腔原発NK/T細胞リンパ腫に対する放射線治療経験会議報告等
- 2012年10月, ANNALS OF ONCOLOGY, 23, 161 - 161, 英語DACARBAZINE MONO-THERAPY FOR UNRESECTABLE NEUROENDOCRINE TUMOR: A RETROSPECTIVE ANALYSIS研究発表ペーパー・要旨（国際会議）
- 2012年09月, LEUKEMIA RESEARCH, 36(9) (9), E202 - E205, 英語[査読有り]速報，短報，研究ノート等（学術雑誌）
- 2012年04月, BONE MARROW TRANSPLANTATION, 47, S201 - S202, 英語Hyperglycaemia during the early phase after haematopoietic stem cell transplantation is caused by the elevation of insulin resistance研究発表ペーパー・要旨（国際会議）
- 2012年02月, BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 18(2) (2), S328 - S329, 英語THE IMPACT OF HCV SERO-POSITIVITY OF RECIPIENTS ON CLINICAL OUTCOMES FOLLOWING ALLOGENEIC HSCT IN JAPAN研究発表ペーパー・要旨（国際会議）
- 2012年02月01日, 日本造血細胞移植学会総会プログラム・抄録集, 34th, 228, 日本語同種造血幹細胞移植後合併症と長期予後に与えるHCV陽性の影響
- 2012年, 日本造血細胞移植学会総会プログラム・抄録集, 34thSMILE療法及び末梢血幹細胞移植によって良好な経過が得られた再発・難治性NK/T細胞リンパ腫の一例
- 2012年, INTERNAL MEDICINE, 51(12) (12), 1579 - 1584, 英語[査読有り]記事・総説・解説・論説等（学術雑誌）
- 科学評論社, 2011年11月, 腫瘍内科, 8巻, 5号, pp. 505-513(5) (5), 409 - 416, 日本語【進化するがん免疫療法(ワクチン療法、細胞療法、抗体療法)】 抗体療法 造血器腫瘍の抗体療法記事・総説・解説・論説等（学術雑誌）
- 南江堂, 2011年06月, 内科, 107巻, 6号, pp. 1351-1354(6) (6), 1355 - 1359, 日本語【内科診療における論点】 血液 急性リンパ性白血病に対する骨髄非破壊的移植前治療を用いた同種造血幹細胞移植の適応をどう考えるか?記事・総説・解説・論説等（学術雑誌）
- 2010年11月, BLOOD, 116(21) (21), 397 - 397, 英語Changes In Incidence and Causes of Non-Relapse Mortality (NRM) After Allogeneic Hematopoietic Cell Transplantation (allo-HCT): Are Transplants Improving?研究発表ペーパー・要旨（国際会議）
- 2009年11月, VOX SANGUINIS, 97, 46 - 46, 英語LONG-TERM FOLLOW UP OF ANTI-HOST A/B ANTIBODY AFTER MINOR ABO-INCOMPATIBLE HEMATOPOIETIC STEM CELL TRANSPLANTATION研究発表ペーパー・要旨（国際会議）
- 2009年11月, BLOOD, 114(22) (22), 1301 - 1302, 英語Renal Complications after Busulfan-Based Reduced-Intensity Stem Cell Transplantation in 286 Patients with Hematological Disorders研究発表ペーパー・要旨（国際会議）
- 2009年02月, BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 15(2) (2), 137 - 138, 英語ABSOLUTE LYMPHOCYTE COUNT KINETICS MAY PREDICT THE CLINICAL OUTCOME AFTER RELATED ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION WITH A BUSULFAN-BASED REDUCED-INTENSITY CONDITIONING REGIMEN研究発表ペーパー・要旨（国際会議）
- 造血幹細胞移植後の類洞閉塞症候群に対するデフィブロタイドの有効性の検討類洞閉塞症候群(SOS)は放射線や化学療法による肝内細静脈や類洞の内皮細胞障害に起因する致死的合併症の一つであるが，未だ治療法は確立されていない。<br>デフィブロタイド(DF)は抗血栓，虚血，炎症作用，血栓溶解作用をもち，血管内皮細胞に特異的に結合し，全身的な抗凝固作用がないという特徴を有する。今回我々は造血幹細胞移植後に類洞閉塞症候群と診断した8例に対してDFを用いた治療を行い，その有効性と副作用について検討した。8例中3例に寛解が得られ，有効例では効果は1週間以内に現れ，肝機能改善のみならず利尿薬に対する反応性の回復と腎機能改善を認めた。経過中，呼吸不全を合併した5例は全例救命することができず，重篤化する前に治療を開始すべきであると考えられた。明らかにDFに起因する副作用は認めず，安全に投与が可能であった。移植後SOSに対しDFは一定の有効性が期待されることから，臨床試験として検証すべきである。一般社団法人 日本血液学会, 2009年, 臨床血液, 50(1) (1), 3 - 8, 日本語
- (一社)日本血液学会-東京事務局, 2008年09月30日, 臨床血液, 49(9) (9), 1125 - 1225, 日本語悪性リンパ腫に対する当院単施設における自家末梢血幹細胞移植を併用したMCEC療法の検討
- 2008年, 臨床血液, 49(9) (9)成人寛解期急性リンパ芽球性白血病における臍帯血移植の有用性
- 2006年11月, BLOOD, 108(11) (11), 888A - 888A, 英語Feasibility of reduced-intensity cord blood transplantation (RICBT) as a salvage therapy for graft failure (GF): Results of a nationwide survey of 63 patients.研究発表ペーパー・要旨（国際会議）
- 2006年10月, EUROPEAN JOURNAL OF HAEMATOLOGY, 77(4) (4), 349 - 354, 英語
- 2006年03月, LEUKEMIA RESEARCH, 30(3) (3), 354 - 361, 英語
- 2005年11月, BLOOD, 106(11) (11), 765A - 765A, 英語The role of transcriptional coactivator TRAP220/MED1 in nuclear receptor-mediated myelomonocytic differentiation.研究発表ペーパー・要旨（国際会議）
- 2005年06月, CANCER GENETICS AND CYTOGENETICS, 159(2) (2), 184 - 186, 英語速報，短報，研究ノート等（学術雑誌）
- Successful treatment with defibrotide for sinusoidal obstruction syndrome after hematopoietic stem cell transplantationSinusoidal obstruction syndrome (SOS) (formerly known as hepatic veno-occlusivedisease (VOD)) is a life-threatening complication subsequent to hematopoietic stem celltransplantation. However, no completely satisfactory strategies for the treatment ofSOS have been established yet. Defibrotide is a single-strandedpolydeoxyribonucleotide with anti-thrombotic, anti-ischemic, anti-inflammatory andthrombolytic properties, but without systemic anticoagulant effects, and someencouraging results have been reported in western countries. We treated fourpatients with defibrotide for SOS, since there seemed to be no possibility to cure thepatients with conventionally available treatments in Japan. All patients showedevidence of multiple organ failure at the start of the treatment. Defibrotide wasadministered intravenously in normal saline in four divided doses for 14 to 27 days.Three patients (75%) responded to the therapy, while one died of SOS andcytomegalovirus infection despite intensive therapy. None of the patients sufferedfrom significant adverse effects such as severe hemorrhage. This is the first reportdealing with the treatment with defibrotide of Japanese patients with SOS. Becausedefibrotide is considered to be promising for the treatment of SOS, it is important tostart a phase II study as soon as possible.神戸大学, 2005年, The Kobe journal of the medical sciences, 51(3) (3), 55 - 65, 英語
- 2004年11月, BLOOD, 104(11) (11), 360A - 360A, 英語Casein kinase I epsilon downregulates PI3K/Akt signaling, followed by genotoxic stress-induced apoptosis of hematopoietic cells.研究発表ペーパー・要旨（国際会議）
- 2003年12月, CANCER GENETICS AND CYTOGENETICS, 147(2) (2), 128 - 133, 英語
- 2003年11月, BLOOD, 102(11) (11), 837A - 837A, 英語Stabilization of SOCS3 and beta-catenin by casein kinase I epsilon to regulate hematopoietic cell differentiation.研究発表ペーパー・要旨（国際会議）
- 2003年11月, BLOOD, 102(11) (11), 263B - 263B, 英語Morphologic, flow cytometric and cytogenetic evaluation of bone marrow involvement in B-cell lymphoma.研究発表ペーパー・要旨（国際会議）
- A novel RDH5 gene mutation in a patient with fundus albipunctatus presenting with macular atrophy and fading white dots.PURPOSE: To report a novel homozygous RDH5 gene mutation in a 76-year-old fundus albipunctatus who developed macular atrophy with the disappearance of white dots. DESIGN: Observational case report. METHODS: Direct genomic sequencing for RDH5 mutations was done after complete ophthalmic examination. RESULTS: Fundoscopy revealed only macular atrophy with notable absence of white dots. A homozygous G490T (Val164Phe) missense RDH5 gene mutation was detected. CONCLUSIONS: This is the first reported long-term case of fundus albipunctatus demonstrating macular atrophy with fading of the typical white dots. Gene studies may be the only method for distinguishing fundus albipunctatus from other types of macular atrophy in the elderly.2003年09月, American journal of ophthalmology, 136(3) (3), 572 - 4, 英語, 国際誌
- 2003年09月, LEUKEMIA & LYMPHOMA, 44(10) (10), 1807 - 1810, 英語
- その他, 南江堂, 2018年, 日本語新臨床腫瘍学 がん薬物療法専門医のために / 電解質異常（高カルシウム血症、低ナトリウム血症）教科書・概説・概論
- その他, 南江堂, 2015年, 日本語電解質異常（高カルシウム血症、低ナトリウム血症） / 新臨床腫瘍学 がん薬物療法専門医のために教科書・概説・概論
- その他, 南江堂, 2013年03月, 日本語がん薬物療法の支持療法マニュアル 〜症状の見分け方から治療まで〜 / がん薬物療法の支持療法マニュアル ?症状の見分け方から治療まで?一般書・啓蒙書
- その他, 南江堂, 2012年12月, 日本語新臨床腫瘍学 がん薬物療法専門医のために / 電解質異常（高カルシウム血症、低ナトリウム血症）教科書・概説・概論
- 共著, 医学書院, 2010年06月, 日本語がん診療レジデントマニュアル 第５版 / 造血幹細胞移植教科書・概説・概論
- 第41回日本造血細胞移植学会総会, 2019年03月, 日本語, 日本造血細胞移植学会, 大阪, 国内会議筋炎症状で発症した節外性NK/T細胞リンパ腫ポスター発表
- 第41回日本造血細胞移植学会総会, 2019年03月, 日本語, 日本造血細胞移植学会, 大阪, 国内会議ポナチニブ投与後に遅発性類洞閉塞症候群を発症した一例ポスター発表
- 第223回日本内科学会近畿地方会, 2019年03月, 日本語, 日本内科学会, 京都, 国内会議ステロイド軟膏の使用中止後に相対的副腎不全をきたした1例口頭発表（一般）
- 第223回日本内科学会近畿地方会, 2019年03月, 日本語, 日本内科学会, 京都, 国内会議EBV関連 sequential lymphomaの1例口頭発表（一般）
- 米国血液学会, 2018年12月, 英語, San Diego, 国際会議Would Bone Marrow be Associated with Superior Outcomes Compared with Peripheral Blood for Male Recipients with Female Donors in HLA-Matched Related Transplantation?ポスター発表
- 第110回近畿血液学地方会, 2018年11月, 日本語, 日本血液学会, 奈良, 国内会議PET/MRI陰性だが頭部造影MRIにて中枢神経浸潤が明らかとなった精巣原発DLBCLの一例口頭発表（一般）
- APBMT, 2018年11月, 英語, アジア太平洋骨髄移植学会, Taipei, 国際会議Nutrition and Rehabilitation of Hematopoietic Stem Cell Transplantation Patientsポスター発表
- 第80回日本血液学会学術集会, 2018年10月, 日本語, 日本血液学会, 大阪, 国内会議多発性筋炎様症状を呈したNK/T細胞リンパ腫ポスター発表
- 第80回日本血液学会学術集会, 2018年10月, 日本語, 日本血液学会, 大阪, 国内会議新たなZMYND11/MBTD1融合遺伝子の発現とt(10;17)(p15;q21)転座を認めたCD7+CD56+急性骨髄性白血病ポスター発表
- 第80回日本血液学会学術集会, 2018年10月, 日本語, 日本血液学会, 大阪, 国内会議シクロスポリン療法後の骨髄移植にて重症肝類洞閉塞症候群をきたした一例ポスター発表
- 第80回日本血液学会学術集会, 2018年10月, 日本語, 日本血液学会, 大阪, 国内会議TLR9の一塩基多型により無症候性CMV感染症を呈した再生不良性貧血の一例.ポスター発表
- 第80回日本血液学会学術集会, 2018年10月, 英語, 日本血液学会, 大阪, 国内会議Discontinuation of sorafenib can lead to the emergence of FLT3-ITD-positive actute myeloid leukemia.ポスター発表
- 第80回日本血液学会学術集会, 2018年10月, 日本語, 日本血液学会, 大阪, 国内会議CLLとの鑑別を要したt(18;22)(q21;q11)を伴う白血化で発症した濾胞性リンパ腫ポスター発表
- 第80回日本血液学会学術集会, 2018年10月, 英語, 日本血液学会, 大阪, 国内会議Aplastic anemia that developed asymptomatic CMV infection due to a single nucleotide polymorphism of TLR9ポスター発表
- 第16回日本臨床腫瘍学会, 2018年07月, 英語, 日本臨床腫瘍学会, 神戸, 国内会議Synchronous esophageal cancer and multiple myeloma: a report of two casesポスター発表
- 第40回日本造血細胞移植学会総会, 2018年02月, 日本語, 日本造血細胞移植学会, 札幌, 国内会議類洞閉塞症候群（SOS/VOD）のリスクファクター、検査・早期診断および治療 ー新ガイドラインの解説も含めた最近の潮流ー公開講演，セミナー，チュートリアル，講習，講義等
- 第40回日本造血細胞移植学会総会, 2018年02月, 日本語, 日本造血細胞移植学会, 札幌, 国内会議非血縁者間骨髄移植前の病勢コントロールとしてGCD療法が有効であった肝脾原発T細胞性リンパ腫の一例ポスター発表
- 第40回日本造血細胞移植学会総会, 2018年02月, 日本語, 日本造血細胞移植学会, 札幌, 国内会議同種造血幹細胞移植の経過中に集中治療を要した患者の検討口頭発表（一般）
- 第40回日本造血細胞移植学会総会, 2018年02月, 日本語, 日本造血細胞移植学会, 札幌, 国内会議造血幹細胞移植病棟における疑義照会の後方視的検討口頭発表（一般）
- 第40回日本造血細胞移植学会総会, 2018年02月, 日本語, 日本造血細胞移植学会, 札幌, 国内会議自家末梢血幹細胞移植における栄養状態と予後に関する方視的解析ポスター発表
- 第40回日本造血細胞移植学会総会, 2018年02月, 日本語, 日本造血細胞移植学会, 札幌, 国内会議血縁ドナーにおける血液成分分離装置Spectra OptiaとCOBE Spectraの採取データの比較検討ポスター発表
- ASBMT/CIBMTR tandem meetings 2018, 2018年02月, 英語, ASBMT/CIBMTR, Salt Lake City, USA, 国際会議Pharmacokinetics of intravenous mycophenolate mofetil after hematopoietic stem cell transplantation in Japanese populationポスター発表
- 第40回日本造血細胞移植学会総会, 2018年02月, 日本語, 日本造血細胞移植学会, 札幌, 国内会議Pharmacokinetics of intravenous mycophenolate mofetil after cord blood transplantation in Japanese口頭発表（一般）
- 第79回日本血液学会学術集会, 2017年10月, 日本語, 日本血液学会, 東京, 国内会議Retrospective analysis of TLS risk in lymphoma patients stratified by cholinesterase levelポスター発表
- 第79回日本血液学会学術集会, 2017年10月, 英語, 日本血液学会, 東京, 国内会議Retrospective analysis of the ESHAP regimen for malignant lymphoma in Kobe University Hospital.ポスター発表
- 第79回日本血液学会学術集会, 2017年10月, 日本語, 日本血液学会, 東京, 国内会議MYC amplification in the form of ring chromosomes 8 in acute myeloid leukemia with t(11;16)(q13;p11)ポスター発表
- 第15回日本臨床腫瘍学会学術集会, 2017年07月, 日本語, 日本臨床腫瘍学会, 神戸, 国内会議Establishment and Gene Expression Analysis of a Double-Hit Lymphoma Cell Lineポスター発表
- 第107回近畿血液学地方会, 2017年06月, 日本語, 日本血液学会, 京都, 国内会議慢性C型肝炎治療後に発症したB細胞性前リンパ球性白血病の一例口頭発表（一般）
- 第31回ヘルペスウイルス研究会, 2017年06月, 日本語, 第31回ヘルペスウイルス研究会, 松江, 国内会議造血幹細胞移植後のT細胞におけるCD134(OX40）の発現が、移植後HHV-6B再活性化および増殖の誘因となる口頭発表（一般）
- 兵庫県皮膚科医会 第116回総会・学術集談会, 2017年06月, 日本語, 兵庫県皮膚科医会, 神戸, 国内会議メトトレキサート関連リンパ増殖性疾患により生じた下腿潰瘍の一例口頭発表（一般）
- Annual Meeting of the American Association for Cancer Research 2017, 2017年04月, 英語, American Asociation for Cancer Research, Washington DC, USA, 国際会議MicroRNA-7 suppresses RB1 expression leading to chromosomal instability in leukemia cells harboring c-Kit mutationポスター発表
- 第39回日本造血細胞移植学会, 2017年03月, 日本語, 日本造血細胞移植学会, 島根, 国内会議難治性の口唇慢性GVHDに対して湿潤療法が著効した一例ポスター発表
- 第39回日本造血細胞移植学会総会, 2017年03月, 日本語, 日本造血細胞移植学会, 松江, 国内会議肝中心静脈閉塞症（VOD）モデルマウスを用いた肝静脈閉塞への好中球細胞外トラップ（NETs）関与の可能性口頭発表（一般）
- 第39回日本造血細胞移植学会, 2017年03月, 日本語, 日本造血細胞移植学会, 島根, 国内会議デフィブロタイド、トロンボモジュリン製剤の遅発性類洞閉塞症候群に対する治療効果口頭発表（一般）
- 第39回日本造血細胞移植学会総会, 2017年03月, 日本語, 日本造血細胞移植学会, 松江, 国内会議シクロスポリンAが自家末梢血幹細胞移植後の再発に有効であった皮膚γδＴ細胞リンパ腫の一例ポスター発表
- 第78回日本血液学会学術集会, 2016年10月, 日本語, 日本血液学会, 横浜, 国内会議類洞閉塞症候群に対する早期治療戦略口頭発表（一般）
- 第78回日本血液学会学術集会, 2016年10月, 日本語, 日本血液学会, 横浜, 国内会議抗ARS抗体陽性間質性肺炎と甲状腺機能低下症に合併した後天性血友病Aポスター発表
- 第78回日本血液学会学術集会, 2016年10月, 日本語, 日本血液学会, 横浜, 国内会議The antiemetic effect of palonosetron in malignant lymphoma patients treated with the CHOP regimenポスター発表
- 第78回日本血液学会総会, 2016年10月, 日本語, 日本血液学会, 横浜, 国内会議Ph陽性慢性骨髄性白血病にみられた先天的バーキット様相互転座ｔ（8；22）（ｑ24；ｑ11．2）ポスター発表
- 21st Congress of APBMT, 2016年10月, 英語, Asia-Pacific Blood and Marrow Transplantation Group, Singapore, Singapore, 国際会議LONG-TERM FOLLOW-UP OUTPATIENT PROGRAM AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION口頭発表（一般）
- 第78回日本血液学会学術集会, 2016年10月, 日本語, 日本血液学会, 横浜, 国内会議Impact of TBI on engraftment and non-relapse mortality in unrelated HCT口頭発表（一般）
- 21st Congress of APBMT, 2016年10月, 英語, Asia-Pacific Blood and Marrow Transplantation Group, Singapore, Singapore, 国際会議EFFECTIVENESS OF THE HEMATOPOIETIC STEM CELL TRANSPLANTATION TEAM-BASED MEDICINE MEETINGS IN HYOGO PREFECTUREポスター発表
- 第78回日本血液学会学術集会, 2016年10月, 日本語, 一般社団法人 日本血液学会, 横浜, 国内会議Early initiation of defibrotide or thrombomodulin treatment for sinusoidal obstruction syndrome口頭発表（一般）
- 21st Congress of APBMT, 2016年10月, 英語, Asia-Pacific Blood and Marrow Transplantation Group, Singapore, Singapore, 国際会議DEFIBROTIDE OR THROMBOMODULIN TREATMENT FOR SINUSOIDAL OBSTRUCTION SYNDROME AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN AND ADULTSポスター発表
- 第78回日本血液学会学術集会, 2016年10月, 日本語, 日本血液学会, 横浜市, 国内会議Coexpression of NUP98/TOP1 and TOP1/NUP98 in de novo AML with t(11;20)(p15;q12) and t(2;5)(q33;q31)ポスター発表
- 第78回 日本血液学会総会, 2016年10月, 日本語, 日本血液学会, 横浜, 国内会議BRAF V600E mutation-specific antibody for the diagnosis of hairy cell leukemia .ポスター発表
- The 21st Annual Congress of Asia Pacific Blood and Marrow Transplantation Group 2016, 2016年10月, 英語, Asia-Pacific Blood and Marrow Transplantation Group, Singapore, Singapore, 国際会議A REDUCED INTENSITY CONDITIONING REGIMEN USING FLUDARABINE AND BUSULFAN (FLU-BU2)ポスター発表
- 第213回日本内科学会近畿地方会, 2016年09月, 日本語, 日本内科学会, 大阪, 国内会議リンパ節生検で完全梗塞が認められ診断に難渋したホジキンリンパ腫の1例口頭発表（一般）
- 第14回日本臨床腫瘍学会学術集会, 2016年07月, 日本語, 日本臨床腫瘍学会, 神戸, 国内会議発熱性好中球減少症における質量分析を用いた菌種同定の有用性についての検討口頭発表（一般）
- 第14回日本臨床腫瘍学会学術集会, 2016年07月, 日本語, 日本臨床腫瘍学会, 神戸, 国内会議同種造血幹細胞移植後のリンパ球回復と予後に関する後方視的解析口頭発表（一般）
- 第14回日本臨床腫瘍学会, 2016年07月, 日本語, 日本臨床腫瘍学会, 神戸市, 国内会議造血器悪性腫瘍に対する化学療法中のD-indexと口腔内感染性合併症との関連についての検討口頭発表（一般）
- 第14回日本臨床腫瘍学会学術集会, 2016年07月, 日本語, 日本臨床腫瘍学会, 神戸, 国内会議急性骨髄性白血病に対するヘッジホッグ阻害薬投与の治療反応性バイオマーカーとしてのNANOG発現口頭発表（一般）
- 第14回日本臨床腫瘍学会学術集会, 2016年07月, 日本語, 日本臨床腫瘍学会, 神戸, 国内会議肝移植後のリンパ増殖性疾患に対する治療戦略口頭発表（一般）
- 第14回日本臨床腫瘍学会学術集会, 2016年07月, 英語, 日本臨床腫瘍学会, 神戸, 国内会議Treatment strategies for double primary neoplasm patients who develop malignant lymphoma and solid tumors口頭発表（一般）
- 第14回日本臨床腫瘍学会学術集会, 2016年07月, 日本語, 日本臨床腫瘍学会, 神戸, 国内会議Quick detection of bacteria with mass spectrometry might reduce mortality in ferile neutropenia口頭発表（一般）
- 第14回日本臨床腫瘍学会学術集会, 2016年07月, 日本語, 日本臨床腫瘍学会, 神戸, 国内会議Mycophenolate Mofetilを使用した造血幹細胞移植後に発症したHHV-6脳炎の治療経過口頭発表（一般）
- 7th, JSH International Symposium, 2016年05月, 英語, 日本血液学会, Awaji, Japan, 国際会議Delayed Absolute Lymphocyte Count Recovery after Allogeneic Hematopoietic Stem Cell Transplantation with Mycophenolate Mofetilポスター発表
- 42nd, Annual Meeting of the European Society for Blood and Marrow Transplantation, 2016年04月, 英語, European Society for Blood and Marrow Transplantation, Valencia, Spain, 国際会議Nationwide Survey of Defbrotide and Recombinant Human Soluble Thrombomodulin for Treatment of Sinusoidal Obstruction Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation口頭発表（一般）
- 42nd, Annual Meeting of the European Society for Blood and Marrow Transplantation, 2016年04月, 英語, European Society for Blood and Marrow Transplantation, Valencia, Spain, 国際会議Absolute Lymphocyte Count Recovery Predicts Clinical Outcome after Allogeneic Hematopoietic Stem Cell Transplantation in a Japanese Populationポスター発表
- 第38回日本造血幹細胞移植学会総会, 2016年03月, 日本語, 日本造血細胞移植学会, 名古屋, 国内会議自律神経ストームを伴った造血幹細胞移植後HHV-6脳炎口頭発表（一般）
- 第31回日本静脈経腸栄養学会学術集会, 2016年02月, 日本語, 福岡, 国内会議造血幹細胞移植患者への栄養管理の前後比較口頭発表（一般）
- 第19回日本病態栄養学会, 2016年01月, 日本語, 日本静脈経腸栄養学会, 横浜, 国内会議造血幹細胞移植患者への栄養管理の前後比較口頭発表（一般）
- 第31回日本静脈経腸栄養学会, 2016年01月, 日本語, 日本静脈経腸栄養学会, 横浜, 国内会議造血幹細胞移植患者へのNEST介入前後の栄養評価口頭発表（一般）
- 第19回日本病態栄養学会年次学術集会, 2016年01月, 日本語, 日本病態栄養学会, 横浜, 国内会議造血幹細胞移植患者へのNEST介入前後の栄養評価口頭発表（一般）
- 第210回日本内科学会近畿地方, 2015年11月, 日本語, 日本内科学会, 神戸, 国内会議超高齢で発症した発作性夜間血色素尿症の1例。口頭発表（一般）
- 第210回日本内科学会近畿地方, 2015年11月, 日本語, 日本内科学会, 神戸, 国内会議診断に難渋したhairy cell leukemiaの一例。口頭発表（一般）
- 第20回アジア太平洋造血細胞移植学会年次学術集会, 2015年10月, 英語, アジア太平洋造血細胞移植学会, 沖縄, 国際会議Retrospective Analysis of 384 Patients Diagnosed with Sinusoidal Obstruction Syndrome (SOS) who were not Treated with Defibrotide or Thrombomodulin: Historical Control Data for Prospective Trials of New Investigational Drugs for SOS[招待有り]口頭発表（招待・特別）
- 第20回アジア太平洋造血細胞移植学会年次学術集会, 2015年10月, 英語, アジア太平洋造血細胞移植学会, 沖縄, 国際会議Physical Functioning and Quality of Life of Patients Who Underwent Hematopoietic Stem Cell Transplantation: Impact of the Supports Provided at the Long-term Follow-up Unit口頭発表（一般）
- 第77回日本血液学会学術集会, 2015年10月, 英語, 日本血液学会, 金沢, 国内会議Mixed phenotype acute leukemia with t(12;17)(p13;q21)/TAF15-ZNF384 and der(1;18)(q10;q10)ポスター発表
- 第20回アジア太平洋造血細胞移植学会年次学術集会, 2015年10月, 英語, アジア太平洋造血細胞移植学会, 沖縄, 国際会議Herpesvirus 6 Encephalitis after Hematopoietic Stem Cell Transplantation with Administration of Mycophenolate Mofetil for Graft-versus-host Disease Prophylaxis in Japan: a Single Institution Experience.ポスター発表
- 第77回日本血液学会学術集会, 2015年10月, 英語, 日本血液学会, 金沢, 国内会議A case of scopulariopsis pneumonia with acute myeloid leukemiaポスター発表
- 第77回日本血液学会学術集会, 2015年10月, 英語, 日本血液学会, 金沢, 国内会議A case of myeloid sarcoma with myelofibrosis secondary to polycthemia veraポスター発表
- 第7回日本静脈経腸栄養学会近畿支部学術集会, 2015年07月, 日本語, 京都, 国内会議造血幹細胞移植患者へのNST介入の評価口頭発表（一般）
- 第13回日本臨床腫瘍学会学術集会, 2015年07月, 英語, 日本臨床腫瘍学会, 札幌, 国内会議A phase 1b study of panobinostat and 5-azacitidine in Japanese patients with MDS, CMML, or AML口頭発表（一般）
- the 6th JSH International Symposium, 2015年05月, 英語, 日本血液学会, 軽井沢, 国内会議Absolute Lymphocyte Count Recovery Predicts Clinical Outcomes after Allogeneic Hematopoietic Stem Cell Transplantationポスター発表
- 第112回日本内科学会総会, 2015年04月, 日本語, 日本内科学会, 京都, 国内会議化学療法中の固形腫瘍患者に対するインフルエンザワクチン2回接種法の有効性と安全性.口頭発表（一般）
- 日本薬学会第135年会, 2015年03月, 日本語, 日本薬学会, 神戸, 国内会議造血幹細胞移植患者に対する栄養管理への介入とその評価ポスター発表
- 第38回日本造血幹細胞移植学会総会, 2015年03月, 日本語, 日本造血細胞移植学会, 名古屋, 国内会議骨髄非破壊的造血幹細胞移植後の非感染性心内膜炎口頭発表（一般）
- 第37回日本造血細胞移植学会総会, 2015年03月, 英語, 日本造血細胞移植学会, 神戸, 国内会議骨髄非破壊的造血幹細胞移植後の非感染性心内膜炎口頭発表（一般）
- 第207回近畿地方会, 2015年03月, 日本語, 日本内科学会, 大阪, 国内会議胃がんに対する胃切除を含め積極的治療介入が奏功した高齢者血管内リンパ腫ポスター発表
- 日本臨床腫瘍薬学会学術大会2015, 2015年03月, 日本語, 日本臨床腫瘍薬学会, 京都, 国内会議『抗がん薬の安全な取り扱いと曝露対策に関するプロジェクト』の取り組み－散剤調剤時の曝露状況について－口頭発表（一般）
- 第54回 神戸血液病研究会, 2015年02月, 日本語, 神戸血液病研究会, 神戸, 国内会議急性骨髄性白血病に対して同種骨髄移植後にCandida Parapsilosis による横紋筋融解症を呈した1例口頭発表（一般）
- 56th Meeting of the American Society of Hematology, 2014年12月, 英語, American Society of Hematology, サンフランシスコ, 国際会議Efficacy of the Two-Dose Influenza Vaccine in Cancer Patients Receiving Chemotherapy: A Prospective Study.ポスター発表
- 第76回日本血液学会総会, 2014年11月, 英語, 日本血液学会, 大阪, 国内会議Rapid recovery of lymphocyte counts after stopping MTX treatment might predict following regression of MTX-LPD.ポスター発表
- 第76回日本血液学会学術集会, 2014年10月, 英語, 日本血液学会, 大阪, 国内会議MYC amplification in the form of double minute chromosomes in two cases of acute myeloid leukemia.ポスター発表
- 第76回日本血液学会学術集会, 2014年10月, 英語, 日本血液学会, 大阪, 国内会議A case of spontaneous hemophilia B diagnoses in adulthoodポスター発表
- 第201回日本内科学会近畿地方会, 2014年09月, 日本語, 日本内科学会, 京都, 国内会議骨髄異形成症候群に結核性多発膿瘍を併発した1例。口頭発表（一般）
- 第52回日本癌治療学会学術集会, 2014年08月, 日本語, 日本癌治療学会, 横浜, 国内会議当院における『抗がん薬の安全な取り扱いと曝露対策に関するプロジェクト』の取り組みポスター発表
- 第12回日本臨床腫瘍学会学術集会, 2014年07月, 日本語, 日本臨床腫瘍学会, 福岡, 国内会議当院における『抗がん薬の安全な取り扱いと曝露対策に関するプロジェクト』の取り組み-散薬服用時の曝露状況について-口頭発表（一般）
- 第12回日本臨床腫瘍学会学術集会, 2014年07月, 日本語, 日本臨床腫瘍学会, 福岡, 国内会議気道狭窄を伴う異なる頸部悪性腫瘍の2例ポスター発表
- 第12回日本臨床腫瘍学会学術集会, 2014年07月, 日本語, 日本臨床腫瘍学会, 福岡, 国内会議A prospective study of the efficacy of influenza vaccination for cancer patients receiving chemotherapy口頭発表（一般）
- 第307回公益社団法人日本医学放射線学会関西地方会(第379回レントゲンアーベント), 2014年06月, 日本語, 公益社団法人日本医学放射線学会関西地方会, 大阪, 国内会議当院におけるゼヴァリンの初期経験口頭発表（一般）
- EHA, 2014年06月, 英語, EHA, ミラノ, イタリア, 国際会議Poor Prognosis of Patients with Severe Sinusoidal Obstruction Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation in Japanese population: On Behalf of Complications Working Group of the Japan Society for Hematopoietic Cell Transplantation (Jポスター発表
- 第36回日本造血細胞移植学会総会, 2014年03月, 英語, 日本造血細胞移植学会, 沖縄, 国内会議同種造血幹細胞移植後の類洞閉塞症候群の発症割合、リスク因子ならびに治療法に関する研究口頭発表（一般）
- ASH, 2013年12月, 英語, American Society of Hematology, New Orleans, USA, 国際会議Nationwide Survey of Sinusoidal Obstruction Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation: Incidence, Risk Factors, and Outcome: On Behalf of Complications Working Group of the Japan Society for Hematopoietic Cell Transplantation (JSHCポスター発表
- 55th ASH Annual Meeting and Exposition, 2013年12月, 英語, American Society of Hematology, New Orleans, USA, 国際会議Gvhd Prophylaxis With Mycophenolate Mofetil and Clacineurin Inhibitor In Allogeneic Hematopoietic Cell Transplantation From HLA-Matche SibligsOr 7-8/8HLA-Matched Unrelated Volunteer Donors;A Japanese,Multicenter,Phase II Trial口頭発表（一般）
- 第75回日本血液学会学術集会, 2013年10月, 日本語, 日本血液学会, 札幌, 国内会議Results of a retrospective study about MTX-LPD and a puestionnaire 'How I treat MTX-LPD'ポスター発表
- 第75回日本血液学会学術集会, 2013年10月, 日本語, 日本血液学会, 札幌, 国内会議Extramedullary T-lymphoid crisis of ETV6/ABL1-positive myeloproliferative neoplasm with t(7;14)ポスター発表
- 第75回日本血液学会学術集会, 2013年10月, 英語, 日本血液学会, 札幌, 国内会議A case of primary cardiac intermediate Burkitt / Diffuse large B cell lymphomaポスター発表
- 第37回日本頭頸部癌学会, 2013年06月, 日本語, 日本頭頸部癌学会, 新宿、東京（京王プラザホテル）, 国内会議鼻腔原発NK／T細胞リンパ腫に対する放射線治療経験ポスター発表
- The 17th meeting of Asia Pacific Blood and Marrow Transplantation Group, 2012年10月, 英語, Asia Pacific Blood and Marrow Transplantation Group, India, Tolvaptan as an alternative treatment for refractory fluid retention associated with sinusoidal obstruction syndrome after allogeneic stem cell transplantation, 国際会議Tolvaptan as an alternative treatment for refractory fluid retention associated with sinusoidal obstruction syndrome after allogeneic stem cell transplantationポスター発表
- The 17th meeting of Asia Pacific Blood and Marrow Transplantation Group, 2012年10月, 英語, Asia Pacific Blood and Marrow Transplantation Group, India, Retrospective analysis of safety and efficacy of (R-) LEED and (R-) MCEC regimens followed by autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma., 国際会議Retrospective analysis of safety and efficacy of (R-) LEED and (R-) MCEC regimens followed by autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma.ポスター発表
- The 17th meeting of Asia Pacific Blood and Marrow Transplantation Group, 2012年10月, 英語, Asia Pacific Blood and Marrow Transplantation Group, India, Candica parapsilosis as a cause for rhabdomyolysis in a patient with acute myeloid leukemia after bone marrow transplantation., 国際会議Candica parapsilosis as a cause for rhabdomyolysis in a patient with acute myeloid leukemia after bone marrow transplantation.ポスター発表
- 第74回日本血液学会学術集会, 2012年10月, 日本語, 日本血液学会, 京都, 国内会議A novel TRB@/NOTCH1 fusion gene in T-cell lymphoblastic lymphoma with t(7;9)(q34;q34)ポスター発表
- 第10回日本臨床腫瘍学会学術集会, 2012年07月, 日本語, 日本臨床腫瘍学会, 大阪, cancer related VTEの現状, 国内会議当科における悪性腫瘍に伴う静脈血栓塞栓症（VTE）の検討ポスター発表
- 第10回日本臨床腫瘍学会学術集会, 2012年07月, 日本語, 日本臨床腫瘍学会, 大阪, 当科においける静脈血栓塞栓症(VTE) 症例の検討, 国内会議当科においける静脈血栓塞栓症(VTE) 症例の検討ポスター発表
- 第10回日本臨床腫瘍学会学術集会, 2012年07月, 日本語, 日本臨床腫瘍学会, 大阪, 切除不能神経内分泌腫瘍に対するダカルバジン単剤療法：後方視的解析, 国内会議切除不能神経内分泌腫瘍に対するダカルバジン単剤療法：後方視的解析ポスター発表
- 第74回日本血液学会学術集会, 2012年06月, 英語, 日本血液学会, 京都, 国内会議Secondary Phiradelphia-positive mixed-phenotype acute leukemia after adjuvant chemotherapy with S-1.ポスター発表
- 38th Annual Meeting of the European Group for Blood and Marrow Transplantation, 2012年04月, 英語, European Group for Blood and Marrow Transplantation, Geneva, Switzerland, 国際会議Hyperglycaemia during the early phase after haematopoietic stem cell transplantation is caused by the elevation of insulin resistanceポスター発表
- 第41回日本皮膚アレルギー・接触皮膚炎学会総会・学術大会, 2011年07月, 日本語, 日本皮膚アレルギー・接触皮膚炎学会, 山梨, 国内会議皮疹を欠くもののHHV-6の再活性化と様々な症状発現を伴い、レクチゾールによるDIHS様変化を呈した1例口頭発表（一般）
- 第33回日本造血細胞移植学会総会, 2011年03月, 日本語, 日本造血細胞移植学会, 松山, 国内会議臍帯血移植前にﾎﾞﾘｺﾅｿﾞｰﾙ水晶体内投与が有効であった真菌性眼内炎ポスター発表
- 第33回日本造血細胞移植学会総会, 2011年03月, 日本語, 日本造血細胞移植学会, 愛媛, 国内会議本邦における同種移植後非再発死亡割合と死因の年次推移：50歳以上成人での検討口頭発表（一般）
- 第33回日本造血細胞移植学会総会, 2011年03月, 日本語, 日本造血細胞移植学会, 愛媛, 国内会議本邦における同種移植後非再発死亡割合と死因の年次推移：49歳以下成人での検討ポスター発表
- 第33回日本造血細胞移植学会総会, 2011年03月, 日本語, 日本造血細胞移植学会, 松山, 国内会議急性GVHD予防薬ﾐｺﾌｪﾉｰﾙ酸ﾓﾌｪﾁﾙ（MMF)使用下における移植後G-CSF至適投与量の検討ポスター発表
- BMT Tandem meetings, 2011年02月, 英語, 米国骨髄移植学会, ホノルル, 米国, 国際会議Day +11 Methotrexate (MTX) might Reduce the Risk of Engraftment Syndrome (ES) and Acute Graftversus-Host Disease (GVHD) after Unrelated Bone Marrow Transplantation (U-BMT) with Reduced-Intensity Conditioning Regimensポスター発表
- 第52回米国血液学会, 2010年12月, 英語, 米国血液学会, オーランド, 米国, 国際会議Engraftment Syndrome (ES) After Reduced-Intensity Stem Cell Transplantation (RIST): ES May Have a Negative Impact on Survival In Standard-Risk Patientsポスター発表
- 第52回米国血液学会, 2010年12月, 英語, 米国血液学会, オーランド, 米国, 国際会議Comparison of Outcomes After Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) In 73 Patients with Follicular Lymphoma (FL), Transformed Follicular Lymphoma (TL), or De Novo Diffuse Large B-Cell Lymphoma (DLBCL): Favorable Outcome for TL Similar toポスター発表
- 第52回米国血液学会, 2010年12月, 英語, 米国血液学会, オーランド, 米国, 国際会議Changes In Incidence and Causes of Non-Relapse Mortality (NRM) After Allogeneic Hematopoietic Cell Transplantation (allo-HCT): Are Transplants Improving?口頭発表（一般）
- 第94回近畿血液学地方会, 2010年11月, 日本語, 近畿血液学地方会, 大津, 国内会議MTX関連リンパ腫の2例口頭発表（一般）
- 第72回日本血液学会総会, 2010年09月, 日本語, 日本血液学会, 横浜, 国内会議フル移植とミニ移植の比較その他
- 第72回日本血液学会総会, 2010年09月, 日本語, 日本血液学会, 横浜, 国内会議Therapy-related pure erythroid leukemia with hemophagocytic syndromeポスター発表
- 第72回日本血液学会総会, 2010年09月, 日本語, 日本血液学会, 横浜, 国内会議Recent changes in non-relapse mortality after allogeneic hematopoietic cell transplantation口頭発表（一般）
- 第72回日本血液学会総会, 2010年09月, 日本語, 日本血液学会, 横浜, 国内会議Engraftment syndrome after reduced-intensity stem cell transplantation口頭発表（一般）
- 第72回日本血液学会総会, 2010年09月, 日本語, 日本血液学会, 横浜, 国内会議A novel dicentric chromosome, dic(9;9)(p12;q34), in follicular lymphoma withaut t(14;18)ポスター発表
- 第31回日本造血細胞移植学会総会, 2009年02月, 日本語, 日本造血細胞移植学会, 札幌, 国内会議造血幹細胞移植後の類洞閉塞症候群に対するデフィブロタイドの有効性の検討口頭発表（一般）
- 第70回日本血液学会総会, 2008年10月, 日本語, 日本血液学会, 京都, 国内会議類洞閉塞症候群(SOS)に対するデフィブロタイドの治療効果判定に経時的な肝門脈血流測定は有用であるポスター発表
- 第70回日本血液学会総会, 2008年10月, 日本語, 日本血液学会, 京都, 国内会議成人寛解期急性リンパ芽球性白血病における臍帯血移植の有用性ポスター発表
- 第70回日本血液学会総会, 2008年10月, 日本語, 日本血液学会, 京都, 国内会議原発性硬化性胆管炎(PSC)経過中に発症し、生体肝移植後に貧血の改善を示した赤芽球癆(PRCA)の一例ポスター発表